Synthesis of pseudo-geminal-, pseudo-ortho-, and ortho-phosphinyl-oxazolinyl-[2.2]paracyclophanes for use as ligands in asymmetric catalysis. by Whelligan, DK & Bolm, C
 1 
The Synthesis of Pseudo-Geminal, Pseudo-Ortho and Ortho 
Phosphinyl-Oxazolinyl-[2.2]Paracyclophanes for Use as Ligands 
in Asymmetric Catalysis 
 
Daniel K. Whelligan and Carsten Bolm* 
 
*Institut für Organische Chemie der RWTH Aachen, Landoltweg 1, D-52074 Aachen, Germany 
Carsten.Bolm@oc.rwth-aachen.de 
 
 
O
N
PPh2
O
N
PPh2
PPh2
pseudo-geminal pseudo-ortho ortho
O
N
 
 
Abstract 
Syntheses of three regioisomers of aromatic-substituted oxazolinyl-phosphinyl-[2.2]paracyclophanes, 
pseudo-geminal, pseudo-ortho and ortho, have been carried out or, in the latter two cases, newly 
developed. It has therefore been demonstrated that all aromatic-substituted isomers relevant for use as 
chelating ligands for asymmetric catalysis are accessible. These P,N-ligands, along with their 
diastereoisomers, were shown to exhibit widely differing activity and enantioselectivity (up to 89% ee) 
in the Pd-catalyzed asymmetric allylic alkylation reaction. 
 2 
Introduction 
Planar chiral substituted [2.2]paracyclophanes have often been used as ligands in asymmetric 
catalysis.1,2 Perhaps the most famous example is PHANEPHOS, a planar chiral equivalent of BINAP, 
which, amongst other applications,3-7 exhibited a higher activity and enantioselectivity than BINAP in 
the Rh-catalyzed hydrogenation of the tetrahydropyrazine precursor to the HIV protease inhibitor 
Crixivan (86 vs. 56% ee).8 
There are three aromatic disubstitution patterns available to [2.2]paracyclophane which give compounds 
geometrically capable of chelating a metal and therefore applicable as chiral ligands for asymmetric 
catalysts. Despite this, all studies to date have concentrated on the development and use of ligands based 
on only one of these patterns. The closest exception involves the synthesis of iso-FHPC, the pseudo-
geminal analogue of 5-formyl-4-hydroxy[2.2]paracyclophane (FHPC).9-13 FHPC is an established 
precursor to [2.2]paracyclophane Schiff bases, salens14,15 and hydroxy-amines16,17 which have been used 
in asymmetric additions of diorganozincs to aldehydes and imines,18,19 sulfoxidations,20  and the 
trimethylsilylcyanation of benzaldehyde.21 However, to the best of our knowledge, the conversion of 
iso-FHPC into similar ligands and their use in asymmetric catalysis has not yet been published. We 
therefore decided to address this general absence by demonstrating that all three aromatic-disubstituted 
[2.2]paracyclophane isomers can be synthesized using established [2.2]paracyclophane chemistry and 
that they are all effective as ligands in asymmetric catalysis. The compounds chosen were the 
oxazolinyl-phosphinyl-[2.2]paracyclophanes, P,N-ligands22,23 designed by Pelter and Hou.24,25 Hou 
showed that use of the pseudo-geminal isomers gave up to 90% ee in the Pd-catalyzed allylic alkylation 
reaction.26 This paper will describe the syntheses of the pseudo-geminal, pseudo-ortho and ortho 
analogues of these compounds (Figure 1) and compare their effectiveness as ligands in the same allylic 
alkylation reaction. 
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Results and Discussion 
By taking advantage of literature-described directing effects, we were able to synthesize both 
diastereoisomers of each of the three desired aryl-substituted regioisomers of phosphinyl-
oxazolinyl[2.2]paracyclophane 1-3.  iso-Propyl was chosen as the substituent on the oxazoline ring on 
account of the inexpense of the amino alcohol required (valinol) and its effectiveness as a sterically 
demanding group which is not so bulky as to inhibit reactions. 
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Synthesis of Pseudo-Geminal Isomers 
Following previously described syntheses of 1 and similar derivatives,24,25,27,28 racemic carboxylic acid 4 
was converted to the acid chloride, reacted with L-valinol and cyclized under Bryce’s conditions29 to 
give an inseparable mixture of diastereoisomers 5 (Scheme 1). The pseudo-geminal substitution pattern 
was attained by exploiting a directing effect, which occurs during iron-catalyzed bromination.30 The 
resulting bromides 6a and 6b were separable by column chromatography. However, this reaction rarely 
proceeded to completion, even if commercial FeBr2 or FeBr3 was used as catalyst, and bromide 6a often 
had to be used in the next step as an inseparable mixture with 5. The bromides 6 were converted to the 
target compounds 1 by bromo-lithium exchange using t-BuLi followed by reaction with ClPPh2.  
Interestingly, it was found that the diastereomeric phosphines 1a and 1b could be far more easily 
separated from the oxazolinyl[2.2]paracyclophane by-products (resulting from protonation of the lithium 
intermediates), by column chromatography,  if a 3-component solvent system (pentane/DCM/EtOAc 
[20:4:1]) was used instead of the more usual 2-component system (pentane/EtOAc). 
 
The absolute configurations of 1 were checked by preparation of 6a, in the same manner, from 
enantiopure carboxylic acid (–)-(RP) 4.31  
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Synthesis of Pseudo-Ortho Isomers 
The pseudo-ortho substitution pattern was set up early on in the synthesis by starting from dibromide 8, 
prepared according to the procedure by Reich and Cram32a with the improvements of Pye and Rossen8 
and Braddock32b (Scheme 2). Its synthesis involves dibromination of [2.2]paracyclophane to give a 
mixture of isomers from which the highly insoluble pseudo-para dibromide 7 can be crystallized. 
Thermal isomerization of 7 leaves the pure pseudo-ortho dibromide 8 alone in solution after cooling. 
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Dibromide 8 was converted to the mono-carboxylic acid 9 as previously described.33 This was then 
converted to the diastereotopic bromo-oxazolinyl [2.2]paracyclophanes 10 (Scheme 3) in the same 
manner as for the pseudo-geminal compounds described above. Oxazolines 10a and 10b were 
inseparable at this stage, but the corresponding phosphines 2, synthesized by lithiation and reaction with 
ClPPh2, had different Rf values on silica, so could be separated by chromatography. Using the standard 
technique, yields of only 9 and 11%, of 2a and 2b, respectively, were obtained and this was attributed to 
phosphine oxidation during work-up and lengthy chromatographic separation. This was despite 
degassing of the solvents prior to use by bubbling argon through them while under sonication.  
However, during later research with 4-methoxyphenylphosphine derivatives, a novel work-up procedure 
was developed and the yields improved to 34 and 32%. This procedure is described later in the 
‘Asymmetric Catalysis’ section. 
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The absolute configurations of 2a and 2b were determined by the synthesis of 2b from enantiopure 
dibromide (+)-(SP) 8. This was obtained by resolution of the racemate by preparative chiral HPLC (see 
Experimental Section). 
 
Synthesis of Ortho Isomers 
Ortho-substituted phosphinyl-oxazolinyl[2.2]paracyclophanes similar to 3 (Figure 1) have been 
previously synthesized in our group by a metal-phosphine exchange of ortho oxazolinyl-palladacycles.28 
Although efficient, the use of stoichiometric (1.1 eq) palladium acetate is expensive so an alternative 
procedure was sought. Attempted ortho-directed lithiations proved problematic due to competitive 1,2-
addition of the alkyl lithium to the oxazoline, and 1,4-addition to the [2.2]paracyclophane backbone.28 
Hou, however, showed that ortho-lithiation of the diastereotopic mixture of 
oxazolinyl[2.2]paracyclophanes 5, using n-BuLi with TMEDA in Et2O, was successful, and that after 
quenching with PhSSPh or PhSeSePh, a mixture of the desired ortho products, as well as those resulting 
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from lithiation at the benzylic position, were obtained.34,35 An attempt by us to synthesize phosphines 3 
by carrying out Hou’s lithiation and then adding ClPPh2 led to a mixture of products (including 17% 
starting material), none of which could be identified as the desired phosphines 3. 
Hence, the ortho substitution pattern was obtained by ortho lithiation of the carbamate 11 (Scheme 4), a 
reaction which has been shown to proceed readily and highly regioselectively when s-BuLi is used in the 
presence of TMEDA.10,36,37 According to the literature, lithiation of 11 followed by reaction with DMF 
and an acidic work-up leads to the ortho hydroxy-aldehyde FHPC (see Introduction), in 64% yield, due 
to facile hydrolysis of the carbamate during work-up. We desired the carboxylic acid rather than the 
aldehyde, so gaseous CO2 was used as the electrophile in place of DMF. Interestingly, the yield was 
higher and the carbamate was left intact. In view of our synthetic plan, this was actually a useful result 
as it acted as a protecting group during subsequent amidation of the carboxylic acid to give separable 
diastereoisomers 13. The absolute configurations of 13 were determined by synthesis of 13b from 
enantiopure (–)-(RP) 11, which itself was obtained in two steps from enantiopure 
bromo[2.2]paracyclophane. The latter compound was synthesized by monolithiation and protonation of 
enantiopure dibromide 8. Unfortunately, removal of the carbamate from 13 was impossible under acidic 
conditions and forcing basic conditions (NaOH, MeOH, reflux, 20 h), although successful, gave 15 in 
low yields along with the carbamate-migrated by-products 14. The carbamates 14 could only be 
hydrolyzed under yet harsher conditions (KOH, i-PrOH, reflux, 51 h). The overall calculated yields of 
15a and 15b, from 13a and 13b, over these two steps are 69 and 56%, respectively. Strangely, when 
these same conditions were applied to the starting carbamates 13 directly, a reduced overall yield of 15a, 
but increased yield of 15b, was observed (hydrolysis of 13a: 34% of product, 8% of SM; hydrolysis of 
13b: 60% of product, 0% of SM). An attempt was also made to carry out carbamate hydrolysis after 
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formation of the oxazoline 16a, but this was unsuccessful and only the ring-opened product 13a 
(actually the precursor of 16a) could be isolated in 10% yield. 
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On treatment with Tf2O, the hydroxy-amides 15 underwent simultaneous cyclization and triflation38 of 
the phenol group to give oxazolinyl-triflates 18 (Scheme 5). Subsequent nucleophilic aromatic 
substitution of the triflate with Ph2PK gave the desired ortho phosphinyl-oxazolines 3. Inspection of the 
NMR spectra of 3a and 3b is very interesting and reveals information about the compounds’ 
conformations.  The chemical shift of the CH proton in the oxazoline ring (identified by COSY, DEPT 
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and HETCOR NMR experiments) is 3.33 ppm for 3a and 2.99 ppm for 3b. The increased shielding 
occuring in 3b is attributed to delocalization of electron density from the P-lone pair, through the pi-
system, onto the N-atom of the oxazoline ring. Correspondingly, 31P NMR of 3b shows the P-atom to be 
more deshielded (1.48 ppm) than that of 3a (0.20 ppm). In conclusion, 3b must have the oxazoline, P-
lone pair and [2.2]paracyclophane aromatic ring in conjugation, whereas 3a does not. 
 
SCHEME 5 
O
N
OTf
O
N
OTf
18a
18b
O
N
PPh2
3a
O
N
PPh2
3b
15a
15b
1H NMR:
δ
 
= 3.33 ppm
H
H
Tf2O, py
(73%)
Tf2O, py
(73%)
(46%)
Ph2PK
(65%)
Ph2PK
31P NMR:
δ = 0.20 ppm
31P NMR:
δ
 
= 1.48 ppm
1H NMR:
δ
 
= 2.99 ppm
 
 
Asymmetric Catalysis 
Asymmetric allylic alkylation was chosen as a test reaction for the new ligands to make a good 
comparison with Hou’s work with compounds 1.25 As hoped, a different positional isomer of the same 
ligand gave a much higher ee; pseudo-ortho 2a gave 82% ee where the original pseudo-geminal 
derivative gave 56% ee (Table 1).   
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TABLE 1. Palladium-Catalyzed Asymmetric Allylic Alkylation 
Ph Ph
MeO OMe
OAc
O O
+ MeO OMe
O O
Ph Ph
[Pd(C3H5)Cl]2
Ligand
LiOAc, BSA
Toluene
Entry Ligand Time (h) Yield (%)Substitution
1
2
3
4
5
6
7
8
9
10
1a
1b
2a
2b
3a
3b
19a
19b
22ab
22bb
pseudo-gem.
pseudo-gem.
pseudo-ortho
pseudo-ortho
ortho
ortho
pseudo-ortho
pseudo-ortho
pseudo-ortho
pseudo-ortho
6
8
10
10
8
7
5
20
5
20
>98
96
>98
>98
>98
>98
>98
>98
>98
>98
56a
30
82
28
23
47
89
63
89
62
(S)
(S)
(S)
(R)
(S)
(S)
(S)
(R)
(R)
(S)
abs. config.ee (%)
a
 Hou obtained 62% ee (ref. 25). b Pseudo-enantiomer of 2 (see text).
 
 
Rather than simply being an effect of the bite angle at the metal in the active catalyst, this result must 
arise from the chiral environment being entirely different to that of the complex formed with 1a. As 
shown in Figure 2, in 1a, half of the [2.2]paracyclophane backbone shields one side of the active site, 
whereas 2a could form a pseudo C2-symmetric type complex. This argument is especially relevant when 
one considers that the opposite diastereoisomers of the pseudo-ortho ligands gave opposite enantiomers 
of the product (entries 3 and 4), whereas the pseudo-geminal and ortho ligands gave the same 
enantiomer (entries 1, 2, 5 and 6). The latter selectivities must depend more strongly on the 
stereochemistry of the oxazoline substituent than that of the [2.2]paracyclophane backbone and the 
conformations shown in Figure 2 are in accord with this. 
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Hou showed that the allylic alkylation could be optimized by using derivatives of the pseudo-geminal 
compounds with a di(4-methoxyphenyl)phosphinyl group in place of the diphenylphosphinyl group. We 
therefore synthesized such derivatives 19 of the pseudo-ortho compounds (Figure 3), using the same 
technique as for 2, but using (MeOC6H4)2PCl instead of Ph2PCl. These electron rich phosphines were 
found to be more susceptible to oxidation and the oxides could not be reduced by the usual method using 
HSiCl3.8 However, the yields could be improved from 9 and 6% (of 19a and 19b, respectively) to 32 and 
31% by modifying the work-up. Hence, in place of the addition of degassed aq NH4Cl and extraction 
with degassed DCM, 2 equiv of Et3N were added (to quench HCl formed later) along with Et2O and the 
mixture suspended directly onto silica. After drying, this was placed atop a silica column and 
chromatography carried out as quickly as possible t
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Use of compounds 19 as ligands in the allylic alkylation reaction gave improved enantioselectivities of 
89 and 63% ee, respectively (Table 1, entries 7 and 8). Further attempted ligand optimization involved 
the synthesis of compounds 22 (Scheme 6) possessing phenyl-substituted oxazoline units. (It should be 
noted that the Ph-substituted products 22 were pseudo enantiomers of the i-Pr-analogues 2 because D-
phenylglycinol was used. Accordingly, the products from the allylic alkylation reaction were the 
opposite enantiomers.) It was also found that the diastereoisomers could be separated at the amide stage.  
Cyclization to the oxazolines 21 required harsher conditions than the i-Pr analogues; an extra equiv of 
each reagent was added and the mixture heated at 50 °C for a further 4 h. Heating was necessary due to 
the lower solubility of the starting amides 20. Once again, the absolute configurations of 21 were 
assigned by synthesis of 21a from enantiopure (+)-(Sp) 9.   
Three different procedures for the metallation of 21b were tested, including using n-BuLi, t-BuLi (both 
at –78 °C) and s-Bu2Mg.LiCl at rt, a reagent recently described by Knochel as highly effective for the 
metallation of aryl bromides.39 Reaction of the organometallics, generated in these ways, with the 
chlorophosphine gave 70, 33 and 0% of the desired product 22b, respectively.  The reaction starting with 
t-BuLi gave an unidentified by-product which was difficult to separate from the product and that starting 
with Knochel’s reagent gave 29% starting material and 33% oxazolinyl[2.2]paracyclophane, resulting 
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from quenching of the unreacted paracyclophanyl metallic during work-up. Hence, for the metallation of 
the opposite diastereoisomer 21a, n-BuLi became the reagent of choice, but strangely, in this case, the 
procedure was completely unsuccessful. Instead, lithiation at –78 °C gave a mixture of products 
(including one with m/z=487/489, corresponding to addition of a butyl group to the starting material). It 
was hypothesized that problems were arising due to either deprotonation of the oxazoline at the benzylic 
position or migration of the anion resulting from bromo-lithium exchange. To avoid this, the reaction 
was carried out at –95 °C using a diethyl ether/liquid nitrogen bath. The desired product 22a was now 
formed and isolated in 57% yield. Its use as a ligand in allylic alkylation, however, gave the same ee 
(89%) as the i-Pr-oxazoline 19a. Similarly, the diastereoisomer 22b acted with almost the equivalent 
selectivity as 19b.  This is understandable since the phenyl group is only ‘longer’ than the i-Pr group and 
the steric bulk is in fact less (A values (–∆G of interconversion between equatorial and axial substituents 
on a cyclohexane ring): Ph = 2.9, i-Pr = 2.15 kcal mol–1).40 This explanation agrees with the 
conformation of the active catalyst with 2a, proposed in Figure 2. 
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Conclusion 
We have devised synthetic routes to all aromatic-substituted regioisomers of phosphinyl-
oxazolinyl[2.2]paracyclophanes which are relevant for use as chelating ligands in asymmetic catalysis.  
In the allylic alkylation reaction, use of the pseudo-ortho version of a previously reported pseudo-
geminal i-Pr-substituted compound gave higher enantioselectivity. However, the Ph-substituted pseudo-
ortho phosphinyl-oxazolinyl[2.2]paracyclophane was less selective than the published pseudo-geminal 
analogue which shows that the conformation of the active catalyst with the pseudo-ortho ligand forms a 
chiral environment which obeys different rules for selectivity. 
 
Experimental 
All air sensitive manipulations were carried out under an inert atmosphere of Ar. Toluene, THF and 
Et2O for reactions were distilled, under nitrogen, from sodium/benzophenone ketyl radical. DCM for 
reactions was distilled, under nitrogen, from CaH2. Et2O, pentane, petroleum ether, DCM, EtOAc and 
CHCl3 for column chromatography were distilled before use. Flash column chromatography was carried 
out using silica gel (bead size 40-63 µm). Analytical thin layer chromatography (TLC) was performed 
using precoated aluminium-backed plates (silica gel 60 F254) and visualized with UV radiation at 254 
nm, or by staining with a solution of potassium permanganate (3 g), K2CO3 (20 g) and NaOH (5%, 5 
mL) in water (300 mL). 1H, 13C, 31P and 19F NMR spectra were recorded at 300, 400 or 500 MHz and 
are reported as follows: chemical shift (ppm), (number of protons, multiplicity, coupling constant J (Hz), 
assignment, when confirmed by using DEPT, COSY and HETCOR experiments). IR spectra were 
measured as KBr pellets, neat (in the case of liquid compounds) or in CHCl3 solution; absorptions are 
given in wave numbers (cm-1). MS was carried out using EI or CI (methane). Optical rotation 
measurements were conducted at room temperature at a wavelength of 589 nm.  
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(±)-[2.2]Paracyclophane-4-carboxylic acid (4),24 (±)-4,12-dibromo[2.2]paracyclophane (7),32 (±)-4-
bromo[2.2]paracyclophane-12-carboxylic acid (9) (and its enantiopure forms),33 (±)-O-(4-
[2.2]paracyclophanyl) diethylcarbamate (11)10 and 1,3-diphenyl-2-propenyl acetate41 were prepared 
according to literature procedures. Acid 4 was resolved according to Rozenberg’s procedure31 and 
dibromide 7 by preparative chiral HPLC [OD column, 55 mm ID, n-hexane:i-PrOH = 95:5), flow rate = 
30 mL min–1, 2 bar, t(R)-(–) = 17 min, t(S)-(+) = 23 min]; HPLC analysis (Chiralcel OD column, n-hexane:i-
PrOH = 95:5, flow rate = 1 mL min–1, t(R)-(–) = 5.9 min, t(S)-(+) = 7.5 min). 
 
(–)-(S,4RP)- and (+)-(S,4SP)-4-(4-iso-Propyloxazolin-2-yl)[2.2]paracyclophane (5a and 5b) 
Thionyl chloride (16.8 mL, 230.3 mmol) was added to carboxylic acid 4 (10.31 g, 40.91 mmol) and the 
resulting mixture heated at 60 °C for 4 h. The excess thionyl chloride was removed by evaporation and 
the final traces by azeotropic distillation with toluene. The resulting crude acid chloride was dissolved in 
DCM (67 mL) and cooled to 0 °C. A solution of L-valinol (8.36 g, 81.00 mmol) and Et3N (11.4 mL, 
81.00 mmol) in DCM (10 mL) was added, the reaction mixture allowed to warm to rt and stirred for 24 
h. DCM (500 mL) was then added and the solution washed with aq NaHCO3 solution (3.5% w/v, 2 × 
600 mL) and brine (600 mL). The organic phase was dried over MgSO4, filtered, concentrated and dried 
in vacuo to give the crude amide. PPh3 (18.78 g, 71.59 mmol), MeCN (859 mL), CCl4 (6.9 mL, 71.6 
mmol) and Et3N (10.1 mL, 71.6 mmol) were added and the mixture stirred for 18 h. DCM (850 mL) was 
then added and the solution washed with brine (2 × 850 mL), dried over MgSO4, filtered and 
concentrated. Flash column chromatography, gradient elution [pentane/EtOAc (19:1),(9:1)] gave an 
inseparable mixture of the title compounds as a pale yellow solid (11.63 g, 89%); Rf (petroleum 
ether:EtOAc = 8:2) 0.52.   
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A pure sample of (–)-(S,4RP) 5a was prepared in the same manner as that described above, but on a 
smaller scale, from enantiopure (–)-(4RP)-carboxylic acid 4.31 Colorless oil; [α]D20 –170 (c 0.88, CHCl3); 
1H NMR (400 MHz) δ 7.04 (1 H, d, J = 1.7, H-5), 6.61-6.46 (6 H, m, H-7, 8, 12, 13, 15, 16), 4.40 (1 H, 
dd, J = 9.3, 7.7, OCHH), 4.20-4.08 (3 H, m, OCHH, NCH, H-2a), 3.19-2.97 (6 H, m, H-1a, 1b, 9a, 9b, 
10a, 10b), 2.85 (1 H, ddd, J = 12.6, 10.2, 6.6, H-2b), 1.93 (1 H, oct, J = 6.7, CH(CH3)2), 1.11 (3 H, d, J = 
6.7, CH3), 1.01 (3 H, d, J = 6.7, CH3); 13C NMR (100 MHz) δ 163.4, 140.7, 139.8, 139.4, 139.2, 135.6, 
134.6, 134.2, 132.8, 132.6, 132.2, 131.1, 128.4, 72.9, 69.3, 35.9, 35.3, 35.1, 34.9, 32.9, 19.2, 18.2; IR 
(neat, cm–1) νmax 1640 (C=N); MS (EI, m/z) 320 (14), 319 (M+, 57), 276 (M+–i-Pr, 9), 216 (15), 215 
(CH2C6H3(oxazoline)CH2+, 100), 159 (11), 147 (11), 104 (14); HRMS Found 319.193581. C22H25NO 
requires 319.193614. 
 
A pure sample of (+)-(S,4SP) 5b was obtained as a by-product from the synthesis of 1b as a pale yellow 
solid; mp 93.5-95.0 °C; [α]D20 +26 (c 1.20, CHCl3); 1H NMR (400 MHz) δ 7.04 (1 H, d, J = 1.9, H-5), 
6.58 (1 H, dd, J = 8.0, 1.9, H-7), 6.57-6.48 (5 H, m, H-8, 12, 13, 15, 16), 4.37-4.30 (2 H, m, OCHH, H-
2a), 4.17-4.08 (2 H, m, OCHH, NCH), 3.20-2.98 (6 H, m, H-1a, 1b, 9a, 9b, 10a, 10b), 2.87 (1 H, ddd, J 
= 12.9, 10.2, 6.9, H-2b), 1.95 (1 H, oct, J = 6.7, CH(CH3)2), 1.17 (3 H, d, J = 6.7, CH3), 1.05 (3 H, d, J = 
6.7, CH3); 13C NMR (100 MHz) δ 162.9, 140.9, 139.8, 139.3, 139.2, 135.7, 134.6, 134.1, 132.8, 132.6, 
132.2, 131.2, 128.3, 73.0, 69.2, 35.8, 35.3, 34.9, 34.7, 33.4, 19.3, 18.7; IR (KBr, cm–1) νmax 1637 (C=N); 
MS (EI, m/z) 320 (14), 319 (M+, 56), 276 (M+–i-Pr, 8), 216 (16), 215 (CH2C6H3(oxazoline)CH2+, 100), 
159 (10), 147 (10), 104 (13); HRMS Found xxxSUBMITTEDxx. C22H25NO requires xxxxx. 
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(–)-(S,4Sp,13Rp)-4-Bromo-13-(4-iso-propyloxazolin-2-yl)[2.2]paracyclophane (6a)27  
The diastereomeric mixture of oxazolines 5 (0.13 g, 0.40 mmol) was dissolved in dry DCM (11 mL).  
Iron powder (3 mg, 0.05 mmol) was added followed by bromine (0.03 mL, 0.48 mmol) [Note: On larger 
scales, a solution of bromine should be added dropwise, according to the literature procedure.24 and the 
mixture heated at reflux for 16 h. The reaction mixture was washed with saturated NaHCO3 solution (2 
× 10 mL) and brine (10 mL). The organic phase was dried over MgSO4, filtered and concentrated. Flash 
column chromatography, gradient elution [petroleum ether/EtOAc (9:1), (8:2)] gave the title compound 
as a white solid (0.07 g, 42%); Rf (petroleum ether:EtOAc = 8:2) 0.58; mp 131.0-133.0 °C; [α]D20 –5 (c 
1.00, CH2Cl2); 1H NMR (500 MHz) δ 7.19 (1 H, br.s, H-12), 6.64 (1 H, d, J = 1.5, H-5), 6.62 (1 H, dd, J 
= 7.8, 2.0, H-16), 6.58 (1 H, d, J = 7.8, H-15), 6.55 (1 H, d, J = 7.8, H-8), 6.53 (1 H, dd, J = 7.8, 1.5, H-
7), 4.56 (1 H, ddd, J = 13.7, 10.4, 4.1, H-1a), 4.40 (1 H, dd, J = 9.4, 8.2, OCHH), 4.11 (1 H, ddd, J = 9.4, 
8.2, 6.6, NCH), 4.04 (1 H, t, J = 8.2, OCHH), 3.56 (1 H, ddd, J = 12.9, 10.4, 4.1, H-2a), 3.06 (2 H, m, H-
10a, 10b), 3.01 (3 H, m, H-9a, 9b, 1b), 2.93 (1 H, ddd, J = 12.9, 10.4, 4.1, H-2b), 1.89 (1 H, oct, J = 6.6, 
CH(CH3)2), 1.05 (3 H, d, J = 6.6, CH3), 0.89 (3 H, d, J = 6.6, CH3); 13C NMR (75 MHz) δ 163.0, 141.1, 
141.0, 139.2, 138.6, 136.6, 136.0 (C-15), 135.9 (C-5), 134.9 (2 C, s, C-8, 16), 132.9 (C-12), 131.6 (C-7), 
126.3, 73.2 (NCH), 68.7 (OCH2), 35.1 (C-2), 34.9 (C-10), 34.5 (C-9), 33.6 (C-1), 32.5 (CH(CH3)2), 19.6 
(CH3), 18.1 (CH3); IR (KBr, cm–1) νmax 1637 (C=N); MS (CI, methane m/z) 428 (M+C2H5+, 22), 426 
(M+C2H5+, 21), 401 (24), 400 (M+H+, 100), 399 (46), 398 (M+H+, 98), 397 (24), 215 
(CH2C6H3(oxazoline)CH2+, 7). 
 
(–)-(S,4Rp,13Sp)-4-Bromo-13-(4-iso-propyloxazolin-2-yl)[2.2]paracyclophane (6b)27  
Further elution gave the title compound as a white solid (0.08 g, 49%); Rf (petroleum ether:EtOAc = 
8:2) 0.47; mp 147.5-149.0 °C; [α]D20 –104 (c 1.00, CH2Cl2); 1H NMR (500 MHz) δ 7.24 (1 H, br.s, H-
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12), 6.66 (1 H, br.s, H-5), 6.61 (1 H, dd, J = 7.9, 1.8, H-16), 6.56 (1 H, br.s, H-7, 8), 6.55 (1 H, d, J = 
7.9, H-15), 4.53 (1 H, ddd, J = 13.1, 10.0, 4.3, H-1a), 4.42 (1 H, dd, J = 9.5, 8.4, OCHH), 4.13 (1 H, t, J 
= 8.4, OCHH), 4.00 (1 H, m, NCH), 3.54 (1 H, ddd, J = 13.2, 10.0, 4.0, H-2a), 3.09 (3 H, m, H-10a, 10b, 
1b), 3.02 (2 H, m, H-9a, 9b), 2.93 (1 H, ddd, J = 13.2, 10.4, 4.3, H-2b), 1.96 (1 H, oct, J = 6.9, 
CH(CH3)2), 1.16 (3 H, d, J = 6.9, CH3), 0.97 (3 H, d, J = 6.9, CH3); 13C NMR (75 MHz) δ 164.2 (C=N), 
141.2, 140.6, 139.0, 138.6, 136.1, 136.0, 135.1, 134.7, 132.7 (C-12), 131.5, 126.9, 126.6, 73.0 (NCH), 
69.8 (OCH2), 35.4 (C-2), 34.8 (C-10), 34.5 (C-9), 33.2 (C-1), 33.1 (CH(CH3)2), 19.8 (CH3), 18.9 (CH3); 
IR (KBr cm–1) νmax 1643 (C=N); MS (CI, methane, m/z) 428 (M+C2H5+, 20), 426 (M+C2H5+, 21), 401 
(21), 400 (M+H+, 88), 399 (45), 398 (M+H+, 100), 397 (25), 215 (CH2C6H3(oxazoline)CH2+, 7); Anal. 
Found C, 66.08; H, 5.94; N, 3.26.  C22H24BrNO requires C, 66.34; H, 6.07; N, 3.52. 
 
(+)-(S,4Sp,13Rp)-4-Diphenylphosphinyl-13-(4-iso-propyloxazolin-2-yl)[2.2]paracyclophane (1a)25  
t-BuLi (15% w/v solution in n-pentane, 2.3 mL, 4.2 mmol) was added dropwise to a solution of bromide 
6a (0.80 g, 2.00 mmol) in THF (20 mL) at –78 °C to give an orange solution. After stirring for 1.5 h, 
ClPPh2 (0.75 mL, 4.20 mmol) was added dropwise. The resulting pale yellow solution was allowed to 
warm to rt and stirred for 18 h. A degassed (by argon bubbling under sonication), saturated aq solution 
of NH4Cl (10 mL) was added and shaken vigorously. The aq layer was separated and extracted with 
degassed DCM (2 × 14 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated. Flash column chromatography (degassed pentane:DCM:EtOAc = 20:4:1) gave the title 
compound as a white solid (0.63 g, 62%); Rf (petroleum ether:EtOAc = 8:2) 0.64; mp 134.0-137.0 °C; 
[α]D20 +4 (c 0.44, CHCl3); 1H NMR (300 MHz) δ 7.33 (4 H, m, P-C6H5), 7.24 (6 H, m, P-C6H5), 7.06 (1 
H, br.s, H-12), 6.64 (2 H, br.s, H-15, 16), 6.50 (2 H, m, H-7, 8), 5.84 (1 H, dd, JH-P = 7.9, J = 1.5, H-5), 
4.61 (2 H, m, OCHH, H-1a), 4.20 (1 H, td, J = 9.2, 7.0, NCH), 4.10 (1 H, dd, J = 9.2, 7.2, OCHH), 3.49 
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(1 H, m, H-2a), 3.07 (1 H, m, H-10a), 2.85 (5 H, m, H-1b, 2b, 9a, 9b, 10b), 1.92 (1 H, oct, J = 7.0, 
CH(CH3)2), 1.13 (3 H, d, J = 7.0, CH3), 0.92 (3 H, d, J = 7.0, CH3); 13C NMR (75 MHz) δ 162.7 (C=N), 
144.0 (d, JC-P = 17.3, C-4), 141.6, 138.83 (d, JC-P = 14.3), 138.80, 138.6, 138.0 (d, JC-P = 10.7), 137.5 (d, 
JC-P = 13.7), 136.1, 135.0, 134.8, 134.2, 133.7, 133.6 (d, JC-P = 2.4), 133.4 (2C, s), 133.3 (d, JC-P = 2.9), 
133.2, 128.52, 128.49, 128.40, 128.3, 128.2, 128.1, 127.0, 73.8 (NCH), 69.1 (OCH2), 36.3, 34.9, 34.8, 
33.6 (d, JC-P = 14.9, C-2), 32.7 (CH(CH3)2), 20.0 (CH3), 18.5 (CH3); 31P NMR (121 MHz) δ –4.12; IR 
(KBr, cm–1) νmax 1637 (C=N); MS (EI, m/z) 504 (26), 503 (M+, 100), 502 (58), 488 (M+–Me, 18) 460 
(M+–i-Pr, 18), 434 (19), 289 (11), 288 (CH2C6H3(PPh2)CH2+, 38), 287 (18), 208 (16), 198 (19), 178 
(11).  Data agrees with that published.25 
 
(–)-(S,4Rp,13Sp)-4-Diphenylphosphinyl-13-(4-iso-propyloxazolin-2-yl)[2.2]paracyclophane (1b) 25  
Treatment of bromide 6b, according to the procedure for the synthesis of 1a, gave the title compound as 
a white solid (0.46 g, 46%); Rf (petroleum ether:EtOAc = 8:2) 0.67; mp 159.0-161.0 °C; [α]D20 –80 (c 
0.39, CHCl3); 1H NMR (300 MHz) δ 7.35 (4 H, m, P-C6H5), 7.23 (6 H, m, P-C6H5), 7.15 (1 H, br.s, H-
12), 6.62 (2 H, br.s), 6.51 (2 H, m, H-7, 8), 5.83 (1 H, dd, JH-P = 8.2, J = 1.7, H-5), 4.55 (1 H, dd, J = 
9.9, 8.1, OCHH), 4.51 (1 H, m, H-1a), 4.31 (1 H, t, J = 8.1, OCHH), 4.10 (1 H, m, NCH), 3.43 (1 H, m, 
H-2a), 3.06 (1 H, m, H-10a), 2.87 (5 H, m, H-1b, 2b, 9a, 9b, 10b), 2.19 (1 H, oct, J = 6.8, CH(CH3)2), 
1.19 (3 H, d, J = 6.8, CH3), 1.02 (3 H, d, J = 6.8, CH3); 13C NMR (75 MHz) δ 163.5 (C=N), 143.7 (d, JC-
P = 17.2, C-4), 141.1, 139.2 (d, JC-P = 14.3), 138.9, 138.0 (d, JC-P = 10.7), 137.2 (d, JC-P = 13.7), 136.1, 
135.1, 134.8, 134.5, 133.7, 133.6, 133.4 (2C, s), 133.2 (d, JC-P = 4.2), 128.6, 128.52, 128.48, 128.38, 
128.2, 128.1, 127.0, 73.1 (NCH), 69.9 (OCH2), 35.7, 34.9, 34.8, 34.1 (d, JC-P = 15.5, C-2), 32.9 
(CH(CH3)2), 20.0 (CH3), 19.1 (CH3); 31P NMR (162 MHz) δ –5.46; IR (KBr, cm–1) νmax 1624 (C=N); 
MS (EI, m/z) 504 (38), 503 (M+, 100), 502 (67), 488 (M+–Me, 19) 460 (M+–i-Pr, 27), 434 (16), 289 (20), 
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288 (CH2C6H3(PPh2)CH2+, 58), 287 (33), 208 (31), 198 (27), 178 (18).  Data agrees with that 
published.25  
 
(–)-(S,4Rp,12Rp)- and (+)-(S,4Sp,12Sp)-4-Bromo-12-(4-iso-propyloxazolin-2-yl)[2.2]paracyclophane 
(10a and 10b) 
Thionyl chloride (1.35 mL, 18.49 mmol) was added to (±)-bromo-carboxylic acid 933 (1.08 g, 3.28 
mmol) and the resulting mixture heated at 60 °C for 4 h. The excess thionyl chloride was removed by 
evaporation and the final traces by azeotropic distillation with toluene. The resulting crude acid chloride 
was dissolved in DCM (5 mL) and cooled to 0 °C. A solution of L-valinol (0.67 g, 6.50 mmol) and Et3N 
(0.91 mL, 6.50 mmol) in DCM (1 mL) was added and the reaction mixture allowed to warm to rt and 
stirred for 24 h. DCM was then added (60 mL) and the solution washed with aq NaHCO3 solution (3.5% 
w/v, 2 × 70 mL) and brine (70 mL). The organic phase was dried over MgSO4, filtered, concentrated and 
dried in vacuo to give the crude amide. PPh3 (1.51 g, 5.75 mmol), MeCN (69 mL), CCl4 (0.56 mL, 5.75 
mmol) and Et3N (0.81 mL, 5.75 mmol) were added and the mixture stirred for 18 h. DCM (70 mL) was 
then added and the solution washed with brine (2 × 70 mL), dried over MgSO4, filtered and 
concentrated. Flash column chromatography, gradient elution (petroleum ether:EtOAc = 14:1 -> 9:1) 
gave an inseparable mixture of the title compounds as a pale yellow solid (1.04 g, 80%); Rf (petroleum 
ether:EtOAc = 1:4) 0.69. 
A pure sample of (–)-(S,4Rp12Rp)-10a was prepared in the same manner as that described above, but on 
a smaller scale, from enantiopure (–)-(4RP,12Rp)-4-bromo[2.2]paracyclophane-12-carboxylic acid (9).33 
White solid; mp 61.5-63.5 °C; [α]D20 –114 (c 0.95, CHCl3); 1H NMR (300 MHz) δ 7.68 (1 H, br.s, H-
13), 6.65 (1 H, d, J = 1.3, H-5), 6.59 (2 H, br.s, H-15, 16), 6.56 (1 H, dd, J = 7.9, 1.3, H-7), 6.49 (1 H, d, 
J = 7.9, H-8), 4.41 (1 H, m, OCHH), 4.20-4.08 (3 H, m, OCHH, NCH, H-10a), 3.46 (1 H, ddd, J = 13.4, 
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9.7, 1.7, H-2a), 3.20 (1 H, ddd, J = 12.9, 9.7, 6.7), 3.06 (2 H, m), 2.96 (1 H, ddd, J = 12.6, 9.4, 7.2), 2.79 
(2 H, m) 1.87 (1 H, oct, J = 6.7, CH(CH3)2), 1.11 (3 H, d, J = 6.7, CH3), 1.01 (3 H, d, J = 6.7, CH3); 13C 
NMR (75 MHz) δ 163.3 (C=N), 142.0, 140.3, 139.2, 138.8, 135.6, 135.0, 134.94, 134.87, 131.2, 130.3 
(C-13), 128.2, 126.6, 72.9 (NCH), 69.6 (OCH2), 36.1, 35.8, 34.0, 33.1 (CH(CH3)2), 32.5, 19.1 (CH3), 
18.5 (CH3); IR (CHCl3, cm–1) νmax 1639 (C=N); MS (EI, m/z) 400 (12), 399 (M+, 48), 398 (13), 397 (M+, 
47), 356 (M+–iPr, 6), 354 (M+–i-Pr, 6), 216 (17), 215 (CH2C6H3(oxazoline)CH2+, 100), 214 (11), 172 
(5), 159 (11), 147 (9), 146 (5); HRMS Found 397.1042. C22H2479BrNO requires 397.1041. 
Similarly, a pure sample of (+)-(S,4Sp,12Sp)-10b was prepared from enantiopure (+)-(4SP,12Sp)-4-
bromo[2.2]paracyclophane-12-carboxylic acid (9).33 White solid; mp 101.0-102.0 °C; [α]D20 +17 (c 0.89, 
CHCl3); 1H NMR (300 MHz) δ 7.62 (1 H, d, J = 1.5, H-13), 6.62 (1 H, d, J = 1.7, H-5), 6.58 (1 H, d, J = 
7.9), 6.55 (2 H, m), 6.47 (1 H, d, J = 7.7), 4.32 (2 H, m, H-10, OCHH), 4.07 (2 H, m, OCHH, NCH), 
3.45 (1 H, ddd, J = 13.4, 9.9, 1.7), 3.17 (1 H, ddd, J = 13.1, 9.9, 6.7), 3.05 (3 H, m), 2.78 (2 H, m), 1.92 
(1 H, oct, J = 6.7, CH(CH3)2), 1.17 (3 H, d, J = 6.7, CH3), 1.05 (3 H, d, J = 6.7, CH3); 13C NMR (75 
MHz) δ 162.8 (C=N), 142.1, 140.6, 139.0, 138.8, 135.6, 135.0, 134.94, 134.86, 131.3, 130.0 (C-13), 
128.1, 126.6, 73.4 (NCH), 69.3 (OCH2), 35.73, 35.68, 33.5 (2C, s, CH(CH3)2, CH2-CH2), 32.6, 19.4 
(CH3), 18.9 (CH3); IR (KBr, cm–1) νmax 1633 (C=N); MS (EI, m/z) 400 (7), 399 (M+, 29), 398 (11), 397 
(M+, 32), 356 (M+–i-Pr, 5), 354 (M+–i-Pr, 5), 216 (16), 215 (CH2C6H3(oxazoline)CH2+, 100), 214 (25), 
172 (5), 147 (9), 146 (5); HRMS Found 397.1042. C22H2479BrNO requires 397.1041. 
 
(+)-(S,4Rp,12Rp)-4-Diphenylphosphinyl-13-(4-iso-propyloxazolin-2-yl)[2.2]paracyclophane (2a) 
n-BuLi (15% w/v solution in n-hexane, 0.35 mL, 0.81 mmol) was added dropwise to a solution of the 
diastereomeric mixture of bromides 10 (0.22 g, 0.54 mmol) in THF (5.4 mL) at –78 °C to give an orange 
solution. After stirring for 1.5 h, Ph2PCl (0.20 mL, 1.14 mmol) was added dropwise to give a black 
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solution, which slowly became orange. After 10 min, the cooling bath was removed and the reaction 
mixture stirred for a further 3 h. Ordinary ‘wet’ Et3N (0.15 mL, 1.08 mmol) was added followed by Et2O 
(5 mL) and the resulting mixture added to silica gel (2.3 g) and DCM (5 mL). The solvent was 
evaporated to leave the crude product mixture suspended on silica which was added to the top of a 
column of silica gel for flash chromatography, gradient elution (petroleum ether:DCM:EtOAc = 20:3:1 -
> 15:4:1 -> 7:2:1. This gave the title product as a white solid (0.09 g, 34%); Rf (petroleum 
ether:CHCl3:EtOAc = 7:2:1) 0.57; mp 105.0-106.0 °C; [α]D20 +33 (c 0.62, CHCl3); 1H NMR (400 MHz) 
δ 7.60 (1 H, d, J = 1.4, H-13), 7.39 (2 H, m, P-C6H5), 7.36-7.20 (8 H, m, P-C6H5), 6.64 (1 H, dd, J = 7.8, 
1.4, H-15), 6.59 (1 H, d, J = 7.8, H-16), 6.57 (1 H, dd, J = 7.9, 1.8, H-7), 6.49 (1 H, dd, J = 7.9, JH-P = 
5.5, H-8), 5.87 (1 H, dd, JH-P = 8.2, J = 1.8, H-5), 4.33 (1 H, dd, J = 8.8, 7.4, OCHH), 4.18 (1 H, dd, J = 
12.5, 9.4, H-10a), 3.94-3.85 (2 H, m, NCH, OCHH), 3.44 (1 H, ddd, J = 12.8, 10.2, 6.9, H-1a), 3.30 (1 
H, dd, J = 13.7, 10.2, H-2a), 3.08 (1 H, dd, J = 12.8, 10.2, H-1b), 3.01 (1 H, dd, J = 12.5, 9.9, H-9a), 
2.86 (1 H, ddd, J = 12.5, 9.4, 7.7, H-9b), 2.78-2.66 (2 H, m, H-2b, 10b), 1.74 (1 H, oct, J = 6.7, 
CH(CH3)2), 1.00 (3 H, d, J = 6.7, CH3), 0.88 (3 H, d, J = 6.7, CH3); 13C NMR (100 MHz) δ 161.7 
(C=N), 143.0 (d, JC-P = 18.2, C-4), 141.1, 140.2, 139.4, 138.6 (d, JC-P = 9.8), 137.2 (d, JC-P = 11.4), 
136.5 (d, JC-P = 9.8), 136.0, 135.7, 135.3, 134.7, 134.2, 133.8, 133.0, 132.83, 132.76, 130.9 (d, JC-P = 
4.5), 129.1, 128.3, 128.2 (2C, s), 128.1, 128.0, 127.5, 73.6 (NCH), 68.8 (OCH2), 36.2 (C-10), 35.5 (d, 
JC-P = 9.9, C-2), 33.14 (C-1), 33.09 (2 C, s, C-9, CH(CH3)2), 19.3 (CH3), 18.4 (CH3); 31P NMR (121 
MHz) δ –1.03; IR (KBr ???, cm–1) νmax 1636 (C=N); MS (EI, m/z) 504 (36), 503 (M+, 100), 502 (6), 488 
(M+–Me, 3) 460 (M+–i-Pr, 7), 418 (7), 289 (15), 288 (CH2C6H3(PPh2)CH2+, 63), 287 (24), 215 (19), 209 
(12), 178 (9); HRMS Found 503.2378. C34H34PNO requires 503.2378. 
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(–)-(S,4Sp,12Sp)-4-Diphenylphosphinyl-13-(4-iso-propyloxazolin-2-yl)[2.2]paracyclophane (2b) 
Further elution gave the title compound as a white solid (0.09 g, 32%); Rf (petroleum 
ether:CHCl3:EtOAc = 7:2:1) 0.47; mp 115.0-118.0 °C; [α]D20 –49 (c 0.59, CHCl3); 1H NMR (400 MHz) 
δ 7.69 (1 H, br.s, H-13), 7.48 (2 H, m, P-C6H5), 7.34-7.19 (8 H, m, P-C6H5), 6.65 (1 H, d, J = 7.7, 1.4, 
H-15), 6.61 (1 H, d, J = 7.7, H-16), 6.58 (1 H, dd, J = 7.7, 1.3, H-7), 6.49 (1 H, dd, J = 7.7, JH-P = 5.5, 
H-8), 5.86 (1 H, dd, JH-P = 8.2, J = 1.3, H-5), 4.23 (2 H, m, OCHH, H-10a), 3.94 (2 H, m, NCH, 
OCHH), 3.45 (1 H, ddd, J = 12.9, 10.2, 6.9, H-1a), 3.30 (1 H, dd, J = 13.7, 10.2, H-2a), 3.06 (2 H, m, H-
9a, 1b), 2.73 (3 H, m, H-2b, 10b, 9b), 1.51 (1 H, m, CH(CH3)2), 0.98 (3 H, d, J = 6.7, CH3), 0.87 (3 H, d, 
J = 6.9, CH3); 13C NMR (100 MHz) δ 162.7 (C=N), 143.2 (d, JC-P = 18.2, C-4), 140.8, 139.8, 139.5, 
139.1, 139.0, 137.3 (d, JC-P = 12.1), 136.5, 136.4, 136.2, 135.6, 134.9, 134.3, 134.2, 132.8, 132.7, 132.6, 
131.7, 131.6, 131.0, 129.1, 128.2, 128.13, 128.06, 72.9 (NCH), 69.2 (OCH2), 36.5, 35.6 (d, JC-P = 14.9, 
C-2), 34.1, 33.5 (CH(CH3)2), 33.1, 19.5 (CH3), 18.9 (CH3); 31P NMR (162 MHz) δ –0.92; IR (KBr, cm–
1) νmax 1637 (C=N); MS (EI, m/z) 504 (34), 503 (M+, 100%), 502 (12), 488 (M+–Me, 4) 460 (M+–i-Pr, 
8), 418 (8), 289 (15), 288 (CH2C6H3(PPh2)CH2+, 63), 287 (15), 215 (18), 209 (11), 178 (8); HRMS 
Found 503.2379. C34H34PNO requires 503.2378. 
 
(±)-O-[4-(5-Carboxy-[2.2]paracyclophanyl)]diethylcarbamate (12) 
s-BuLi [1.2 M solution in cyclohexane/hexane (92:8), 99.3 mL, 119.2 mmol] was added to a solution of 
carbamate 1110 (32.6 g, 101.0 mmol) and TMEDA (18.2 mL, 121.2 mmol) in THF (1.5 L) at 0 °C. The 
resulting orange solution was stirred for 1.25 h. CO2 gas was then bubbled through the solution for 2 h.  
The reaction mixture was allowed to warm to rt and stirred for 18 h with slow bubbling of CO2. The 
mixture was extracted twice with water (1 L, 500 mL) then aq NaOH solution (6 M, 50 mL). The 
combined aq layers were washed with DCM (500 mL) and Et2O (2 × 500 mL). The aq layer was 
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acidified to pH 1 with aq HCl (6 M) to give a white precipitate. The mixture was then extracted with 
DCM (3 × 500 mL), the combined organic layers were dried over Na2SO4, filtered, concentrated and 
dried in vacuo to give the title compound as a white solid (33.4 g, 90%); Rf (DCM:EtOAc = 8:2) 0.07; 
mp 125.0-127.0 °C; 1H NMR (300 MHz) δ 6.82 (1 H, dd, J = 7.9, 1.7), 6.70 (1 H, dd, J = 7.9, 1.7), 6.67 
(1 H, d, J = 8.2), 6.62 (1 H, dd, J = 7.9, 1.7), 6.53 (1 H, dd, 7.9, 1.7), 6.50 (1 H, d, J = 7.9), 3.59 (2 H, m, 
CH2CH3), 3.50 (1 H, m), 3.39 (2 H, m, CH2CH3), 3.25 (1 H, ddd, J = 12.6, 10.6, 4.9), 3.16-3.04 (4 H, 
m), 2.88 (1 H, ddd, J = 12.6, 10.4, 5.2), 2.79 (1 H, m), 1.42 (3 H, t, J = 6.9, CH2CH3), 1.21 (3 H, t, J = 
7.2, CH2CH3); 13C NMR (75 MHz) δ 170.2, 153.8, 148.1, 142.8, 139.4, 139.3, 137.8, 133.2, 132.9, 
132.7, 132.2, 131.0, 129.2, 125.4, 42.3 (CH2CH3), 42.0 (CH2CH3), 34.7, 34.3 (2 C, s), 30.6, 14.2 (CH3), 
13.2 (CH3); IR (KBr, cm–1) νmax 3433 (O-H), 1723 (Et2NC=O), 1678 (C=OOH); MS (EI, m/z) 368 (17), 
367 (M+, 72), 251 (17), 250 (ParacyclophanylCHO+, 90), 104 (CH2C6H4CH2+, 58), 100 (100); HRMS 
Found 367.1784. C22H25NO4 requires 367.1784. 
 
Enantiopure (+)-(4RP,5SP)-12 was prepared from enantiopure carbamate 1116a (see Results and 
Discussion). White solid; mp 140.0-142.0 °C; [α]D20 +53 (c 0.70, CHCl3). 
 
(–)-(S,4SP,5RP)-O-[4-(5-(1-hydroxymethyl-2-methyl-propylcarbamoyl)-[2.2]paracyclophanyl)]-
diethylcarbamate (13a) 
Thionyl chloride (2.0 mL, 27.8 mmol) was added to (±)-carboxylic acid 12 (1.81 g, 4.94 mmol) and the 
resulting mixture heated at 60 °C for 4 h. The excess thionyl chloride was removed by evaporation and 
the final traces by azeotropic distillation with toluene. The resulting crude acid chloride was dissolved in 
DCM (8 mL) and cooled to 0 °C. A solution of L-valinol (1.01 g, 9.78 mmol) and Et3N (1.37 mL, 9.78 
mmol) in DCM (1 mL) was added and the reaction mixture allowed to warm to rt and stirred for 24 h.  
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DCM (120 mL) was then added and the solution washed with aq NaHCO3 solution (3.5% w/v, 2 × 120 
mL) and brine (120 mL). The organic phase was dried over Na2SO4, filtered and concentrated. Flash 
column chromatography, gradient elution (pentane:DCM:EtOAc = 6:2:2 -> 5:2:3 -> 4:2:4) gave the title 
compound as a white solid (0.85 g, 38%); Rf (DCM:EtOAc = 8:2) 0.21; mp 61.5-63.0 °C; [α]D20 –23 (c 
0.90, CHCl3); 1H NMR (300 MHz) δ 7.10 (1 H, dd, J = 7.9, 1.7), 6.72 (1 H, dd, J = 7.9, 1.7), 6.58 (1 H, 
dd, J = 7.9, 1.7), 6.54 (1 H, d, J = 7.9), 6.52 (1 H, dd, J = 7.9, 1.7), 6.44 (1 H, d, J = 7.9), 5.78 (1 H, br.d, 
J = 8.9, NH), 3.81 (1 H, dddd, J = 8.9, 7.2, 5.4, 3.5, NCH), 3.59 (3 H, m, CH2OH, CH2CH3), 3.44 (1 H, 
m, CHHCH3), 3.28 (1 H, m, CHHCH3), 3.23 (2 H, m), 3.19-2.98 (5 H, m), 2.74 (1 H, m), 1.81 (1 H, oct, 
J = 6.7, CH(CH3)2), 1.43 (3 H, t, J = 7.2, CH2CH3), 1.20 (3 H, t, J = 7.2, CH2CH3), 0.95 (3 H, d, J = 6.7, 
CH(CH3)CH3), 0.91 (3 H, d, J = 6.7, CH(CH3)CH3); 13C NMR (75 MHz) δ 167.1, 154.7, 146.0, 140.0, 
139.2, 138.9, 136.1, 132.8, 132.5, 132.0 (2C, s), 131.6, 129.6, 129.5, 63.3 (CH2OH), 57.3 (NCH), 42.12 
(CH2CH3), 42.08 (CH2CH3), 35.1, 34.5, 33.4, 30.4, 28.9 (CH(CH3)2), 19.5 (CH(CH3)CH3), 18.8 
(CH(CH3)CH3), 14.0 (CH2CH3), 13.2 (CH2CH3); IR (CHCl3, cm–1) νmax 3411 (br., O-H and N-H), 1699 
(Et2NC=O), 1657 (C=OONH); MS (EI, m/z) 453 (21), 452 (M+, 78), 350 (9), 348 (M+–CH2C6H4CH2, 7), 
335 (12), 248 (14), 231 (60), 104 (CH2-C6H4-CH2+, 23), 100 (100); HRMS Found 452.2675. 
C27H36N2O4 requires 452.2675. 
 
(+)-(S,4RP,5SP)-O-[4-(5-(1-hydroxymethyl-2-methyl-propylcarbamoyl)-[2.2]paracyclophanyl)]-
diethylcarbamate (13b) 
Further elution gave the title compound as a white solid (0.58 g, 26%); Rf (DCM:EtOAc = 8:2) 0.10; mp 
136.5-137.0 °C; [α]D20 +20.7 (c 1.09, CHCl3); 1H NMR (300 MHz) δ 7.13 (1 H, dd, J = 7.9, 1.7), 6.67 (1 
H, dd, J = 7.9, 2.0), 6.59 (1 H, dd, J = 7.7, 1.7), 6.53 (1 H, d, J = 7.8), 6.52 (1 H, dd, J = 7.7, 2.0), 6.43 
(1 H, d, J = 7.8), 6.08 (1 H, br.d, J = 7.9, NH), 3.71 (1 H, m, NCH), 3.64 (1 H, m, CHHCH3), 3.52 (3 H, 
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m, CHHCH3, CH2OH), 3.37 (1 H, m, CHHCH3), 3.33-3.17 (3 H, m), 3.06-2.91 (4 H, m), 2.86 (1 H, m), 
2.76 (1 H, m), 1.83 (1 H, oct, J = 6.8, CH(CH3)2), 1.40 (3 H, t, J = 7.2, CH2CH3), 1.18 (3 H, t, J = 7.2, 
CH2CH3), 0.89 (3 H, d, J = 6.8, CH(CH3)CH3), 0.88 (3 H, d, J = 6.8, CH(CH3)CH3); 13C NMR (75 
MHz) δ 167.6, 154.5, 146.0, 140.6, 139.6, 138.8, 136.1, 132.7, 132.5, 132.3, 132.1, 132.0, 129.3, 128.8, 
63.7 (NCH), 57.9 (CH2OH), 42.0 (2C, s, 2×CH2CH3), 35.1, 34.4, 33.4, 30.3, 28.8 (CH(CH3)2), 19.1 
(CH(CH3)CH3), 19.0 (CH(CH3)CH3), 14.2 (CH2CH3), 13.2 (CH2CH3); IR (KBr, cm–1) νmax 3493 (br., O-
H), 3259 (N-H), 1719 (Et2NC=O), 1661 (C=OONH); MS (EI, m/z) 453 (25), 452 (M+, 90), 350 (10), 
348 (M+–CH2C6H4CH2, 7), 335 (14), 248 (14), 231 (60), 104 (CH2C6H4CH2+, 24), 100 (100); HRMS 
Found 452.2676. C27H36N2O4 requires 452.2675. 
 
(–)-(S,4SP,5RP)-O-[2-(5-(4-hydroxy[2.2]-paracyclophanyl))-3-methylbutyl] diethylcarbamate (14a) 
Carbamate 13a (0.85 g, 1.89 mmol) was dissolved in a mixture of MeOH (53 mL) and aq NaOH (6 M, 
19.8 mL, 118.9 mmol). The reaction mixture was then heated at reflux for 20 h. Aq HCl (3 M, 45 mL, 
135 mmol) was added and the mixture extracted with EtOAc (4 × 50 mL). The combined organic layers 
were dried over Na2SO4, filtered and concentrated. Flash column chromatography, gradient elution 
(pentane:EtOAc = 19:1 -> 9:1 -> 8:2 -> 7:3) gave the title compound as a colourless oil (0.26 g, 31%); 
Rf (petroleum ether:EtOAc = 1:1) 0.71; [α]D20 –117 (c 0.95, CHCl3); 1H NMR (300 MHz) δ 11.65 (1 H, 
s, OH), 7.04 (1 H, dd, J = 7.9, 1.7), 6.58 (1 H, dd, J = 7.9, 1.7), 6.48 (1 H, dd, J = 7.7, 1.7), 6.44 (1 H, d, 
J = 7.7), 6.43 (1 H, dd, J = 7.7, 1.7), 6.25 (1 H, d, J = 7.7), 4.25 (2 H, m, NCH, CHHO), 4.06 (1 H, dd, J 
= 15.6, 8.3, CHHO), 3.57 (1 H, m, H-9a), 3.39 (1 H, ddd, J = 12.7, 9.9, 2.7, H-2a), 3.20-2.80 (9 H, m, H-
10a, 10b, 9b, 1a, 1b, 2×CH2CH3), 2.53 (1 H, ddd, J = 12.7, 10.6, 5.2, H-2b), 1.99 (1 H, m, CH(CH3)2), 
1.12 (6 H, d, J = 6.9, CH(CH3)2), 0.93 (6 H, m, 2×CH2CH3); 13C NMR (75 MHz) δ 170.9, 159.5, 155.9, 
140.1, 137.8, 137.5, 137.4, 133.0, 131.8, 131.3, 129.0, 127.7, 127.1, 117.9, 64.6 (CH2OH), 54.3 (NCH), 
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42.0 (CH2CH3), 41.4 (CH2CH3), 36.1, 35.0, 33.8, 30.2 (2 C, s, CH(CH3)2, C-2), 19.6 (CH(CH3)CH3), 
18.9 (CH(CH3)CH3), 13.9 (CH2CH3), 13.1 (CH2CH3); IR (CHCl3, νmax 3309 (O-H and N-H), 1686 
(Et2NC=O), 1624 (C=OONH); MS (EI, m/z) 453 (30), 452 (M+, 100), 348 (M+–CH2C6H4CH2, 30), 347 
(33), 335 (M+–HOC(O)NEt2, 15), 232 (14), 231 (71), 230 (15), 146 (10), 104 (CH2-C6H4-CH2+, 27), 100 
(16); HRMS Found 452.2675. C27H36N2O4 requires 452.2675. 
 
(–)-(S,4SP,5RP)-4-Hydroxy-[2.2]paracyclophane-5-carboxylic acid (1-hydroxymethyl-2-methyl-
propyl)-amide (15a) 
i) Further elution gave the title compound (0.34 g, 51%). 
ii) Alternatively, carbamate 14a (0.22 g, 0.48 mmol) and KOH (0.27 g, 4.8 mmol) were dissolved in i-
PrOH (10 mL). The reaction mixture was then heated at reflux for 51 h. Aq HCl (3 M, 7 mL, 21 mmol) 
was added and the mixture extracted with Et2O (2 × 22 mL) and DCM (22 mL). The combined organic 
layers were washed with NaHCO3 (30 mL), to remove any [2.2]paracyclophane carboxylic acid by-
product, and the aq layer was extracted with DCM (22 mL). All organic layers were combined, dried 
over Na2SO4, filtered and concentrated. Flash column chromatography, gradient elution (pentane:EtOAc 
= 9:1 -> 8:2 -> 7:3) first gave unreacted starting material 14a (0.04 g, 16%) and then the title compound 
as a white solid (0.10 g, 59%); Rf (petroleum ether:EtOAc = 1:1) 0.50; mp 43.0-48.0 °C; [α]D20 –148 (c 
1.30, CHCl3); 1H NMR (400 MHz) δ 11.52 (1 H, s, OH), 7.05 (1 H, dd, J = 8.0, 1.9), 6.59 (1 H, dd, J = 
8.0, 1.9), 6.51 (1 H, dd, J = 8.0, 1.9), 6.48 (1 H, d, J = 7.7), 6.45 (1 H, dd, J = 8.0, 1.9), 6.25 (1 H, d, J = 
7.7), 6.08 (1 H, br.d, J = 8.7, NH), 3.95 (1 H, tdd, J = 8.7, 6.8, 4.1, NCH), 3.68 (2 H, m, CH2OH), 3.53 
(1 H, m, H-9a), 3.48 (1 H, q, J = 7.0), 3.41 (1 H, ddd, J = 12.9, 10.2, 2.8), 3.17 (1 H, ddd, J = 12.9, 10.4, 
5.2), 3.11 (1 H, m), 3.02 (1 H, ddd, J = 12.9, 10.7, 2.8), 2.96-2.82 (2 H, m), 2.55 (1 H, ddd, J = 13.2, 
10.7, 5.2, H-2b), 2.05 (1 H, oct, J = 6.8, CH(CH3)2), 1.10 (3 H, d, J = 6.8, CH3), 1.09 (3 H, d, J = 6.8, 
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CH3); 13C NMR (75 MHz) δ 171.0, 159.4, 140.1, 137.9, 137.7, 137.3, 133.0, 131.8, 131.4, 129.2, 127.7, 
127.1, 117.9, 63.1 (CH2OH), 56.8 (NCH), 36.1, 35.0, 33.8, 30.2, 29.4 (CH(CH3)2), 19.8 (CH3), 19.2 
(CH3); IR (KBr, cm–1) νmax 3419 (br., O-H and N-H), 1622 (C=OONH); MS (EI, m/z) 354 (24), 353 
(M+, 100), 322 (M+–CH2OH, 13), 310 (M+–i-Pr, 21), 268 (34), 250 (33), 249 (M+–CH2C6H4CH2, 52), 
248 (12), 218 (62), 206 (22), 164 (15), 163 (15), 147 (21), 146 (17), 104 (CH2C6H4CH2+, 74), 102 (22); 
HRMS Found 353.1990. C22H27NO3 requires 353.1991. 
 
(+)-(S,4RP,5SP)-O-[2-(5-(4-hydroxy[2.2]-paracyclophanyl))-3-methylbutyl] diethylcarbamate (14b) 
Treatment of carbamate 13b (0.58 g, 1.29 mmol) according to the procedure for the synthesis of 14a 
gave the title compound as a pale yellow solid (0.31 g, 54%); Rf (petroleum ether:EtOAc = 1:1) 0.68; 
mp 111.0-113.0 °C; [α]D20 +74 (c 0.76, CHCl3); 1H NMR (400 MHz) δ 11.42 (1 H, s, OH), 7.04 (1 H, 
dd, J = 7.9, 1.9), 6.57 (1 H, dd, J = 7.9, 1.9), 6.49 (1 H, dd, J = 7.9, 1.9), 6.48 (1 H, d, J = 7.7), 6.44 (1 
H, dd, J = 7.9, 1.9), 6.26 (1 H, d, J = 7.7), 6.02 (1 H, br.d, J = 9.1, NH), 4.40 (1 H, dd, J = 11.5, 5.8, 
CHHO), 4.27 (1 H, dd, J = 11.5, 3.3, CHHO),  4.19 (1 H, m, NCH), 3.47 (1 H, ddd, J = 13.6, 9.3, 2.7, 
H-9a), 3.44-3.30 (5 H, m, H-2a, 2×CH2CH3), 3.17 (1 H, ddd, J = 12.9, 10.2, 5.2, H-1a), 3.04 (2 H, m, H-
1b, 10a), 2.88 (1 H, ddd, J = 13.6, 9.3, 6.7, H-9b),  2.78 (1 H, ddd, J = 12.6, 9.3, 6.7, H-10b), 2.54 (1 H, 
ddd, J = 13.2, 10.7, 5.2, H-2b), 1.88 (1 H, oct, J = 6.8, CH(CH3)2), 1.18 (6 H, t, J = 7.1, 2×CH2CH3), 
0.97 (3 H, d, J = 6.8, CH(CH3)CH3), 0.92 (3 H, d, J = 6.8, CH(CH3)CH3); 13C NMR (100 MHz) δ 170.0, 
159.1, 155.4, 139.9, 137.7, 137.5, 137.2, 132.7, 131.6, 131.2, 128.9, 127.5, 126.9, 118.0, 65.1 (CH2OH), 
54.0 (NCH), 41.9 (CH2CH3), 41.3 (CH2CH3), 35.9, 35.0, 33.8, 30.2, 29.7 (CH(CH3)2), 19.2 
(CH(CH3)CH3), 18.8 (CH(CH3)CH3), 14.2 (CH2CH3), 13.5 (CH2CH3); IR (KBr, cm–1) νmax 3308 (O-H 
and N-H), 1682 (Et2NC=O), 1622 (C=OONH); MS (EI, m/z) 453 (29), 452 (M+, 100), 348 (M+–
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CH2C6H4CH2, 33), 347 (38), 335 (M+–HOC(O)NEt2, 13), 232 (13), 231 (69), 230 (13), 146 (8), 104 
(CH2C6H4CH2+, 21), 100 (15); HRMS Found 452.2674. C27H36N2O4 requires 452.2675. 
 
(+)-(S,4RP,5SP)-4-Hydroxy-[2.2]paracyclophane-5-carboxylic acid (1-hydroxymethyl-2-methyl-
propyl)-amide (15b) 
i) Further elution gave the title compound (0.11 g, 25%). 
ii) Alternatively, treatment of carbamate 14b (0.29 g, 0.64 mmol) according to procedure (ii) for the 
synthesis of 15a first gave the starting material 14b (0.04 g, 12%) and then the title compound as a white 
solid (0.13 g, 58%); Rf (petroleum ether:EtOAc = 1:1) 0.50; mp 85.5-87.0 °C; [α]D20 +58 (c 1.95, 
CHCl3); 1H NMR (400 MHz) δ 11.46 (1 H, s, OH), 7.05 (1 H, dd, J = 7.7, 1.7), 6.59 (1 H, dd, J = 8.0, 
1.7), 6.54 (1 H, dd, J = 7.7, 1.9), 6.49 (1 H, d, J = 7.7), 6.44 (1 H, dd, J = 8.0, 1.9), 6.28 (1 H, d, J = 7.7), 
6.14 (1 H, br.d, J = 8.5, NH), 3.97 (1 H, m, NCH), 3.88 (2 H, m, CH2OH), 3.59 (1 H, m, H-9a), 3.42 (1 
H, ddd, J = 13.0, 10.3, 2.8, H-2a), 3.17 (1 H, ddd, J = 12.6, 10.3, 5.0, H-1a), 3.13 (1 H, m, H-10a), 3.01 
(1 H, ddd, J = 12.6, 10.7, 2.8, H-1b), 2.88 (2 H, m, H-9b, 10b), 2.55 (1 H, ddd, J = 13.0, 10.7, 5.0, H-
2b), 1.91 (1 H, oct, J = 6.9, CH(CH3)2), 0.98 (3 H, d, J = 6.9, CH3), 0.94 (3 H, d, J = 6.9, CH3); 13C 
NMR (100 MHz) δ 170.6, 159.2, 139.8, 137.9, 137.5, 137.4, 132.9, 131.6, 131.2, 129.0, 127.4, 127.2, 
117.9, 63.6 (CH2OH), 56.7 (NCH), 36.3, 35.0, 33.8, 30.1 (C-2), 29.1 (CH(CH3)2), 19.5 (CH3), 19.0 
(CH3); IR (CHCl3, cm–1) νmax 3434 (br., O-H and N-H), 1619 (C=OONH); MS (EI, m/z) 354 (22), 353 
(M+, 100), 322 (M+–CH2OH, 15), 310 (M+–i-Pr, 25), 268 (38), 250 (28), 249 (M+–CH2C6H4CH2, 46), 
248 (14), 218 (56), 206 (19), 164 (14), 163 (13), 147 (13), 146 (11), 104 (CH2C6H4CH2+, 44), 102 (18); 
HRMS Found 353.1991. C22H27NO3 requires 353.1991. 
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(–)-(S,4SP,5RP)-O-[4-(5-(4-Isopropyloxazolin-2-yl)-[2.2]paracyclophanyl)]diethylcarbamate (16a) 
Carbamate 13a (65 mg, 0.143 mmol) was dissolved in MeCN (3.0 mL) and PPh3 (65 mg, 0.250 mmol), 
Et3N (35 µl, 0.250 mmol) and CCl4 (24 µl, 0.250 mmol) were added. The resulting solution was stirred 
for 23 h. It was then diluted with DCM (3 mL), washed with brine (2 × 3 mL) and dried over Na2SO4.  
The mixture was filtered and concentrated. Flash column chromatography, gradient elution 
(pentane:EtOAc = 9:1 -> 8:2 -> 7:3) gave the title compound as a colorless oil which became a white 
crystalline solid on standing (35 mg, 56%); Rf (petroleum ether:EtOAc = 8:2) 0.12; mp 62.0-64.0 °C; 
[α]D20 –50 (c 0.79, CHCl3); 1H NMR (400 MHz) δ 6.98 (1 H, dd, J = 7.7, 1.9), 6.71 (1 H, dd, J = 7.7, 
1.9), 6.60 (1 H, dd, J = 8.0, 1.9), 6.58 (1 H, d, J = 8.0), 6.53 (1 H, dd, J = 8.0, 1.9), 6.46 (1 H, d, J = 8.0), 
4.25 (1 H, dd, J = 9.6, 8.0, CHHO), 4.08 (1 H, ddd, J = 9.6, 8.0, 6.6, NCH), 3.98 (1 H, t, J = 8.0, 
CHHO), 3.68 (1 H, m, CHHCH3), 3.52 (1 H, ddd, J = 12.6, 10.6, 2.5, H-9a), 3.44 (2 H, m, 2×CHHCH3), 
3.30 (1 H, m, CHHCH3), 3.21 (1 H, ddd, J = 12.4, 10.6, 4.7, H-10a), 3.10 (1 H, m, H-2a), 3.04 (3 H, m, 
H-1a, 1b, 10b), 2.87 (1 H, ddd, J = 12.6, 10.4, 4.7, H-9b), 2.75 (1 H, m, H-2b), 1.82 (1 H, oct, J = 6.6, 
CH(CH3)2), 1.41 (3 H, t, J = 6.9, CH2CH3), 1.18 (3 H, t, J = 7.1, CH2CH3), 1.09 (3 H, d, J = 6.6, 
CH(CH3)CH3), 0.98 (3 H, d, J = 6.6, CH(CH3)CH3); 13C NMR (100 MHz) δ 160.4, 153.3, 148.2, 142.2, 
139.4, 139.2, 136.2, 132.8, 132.5, 132.3, 131.5, 131.1, 129.3, 123.1, 73.3 (NCH), 69.3 (CH2O), 42.2 
(CH2CH3), 42.0 (CH2CH3), 34.8, 34.4, 34.1, 33.2 (CH(CH3)2), 30.7 (C-2), 19.2 (CH(CH3)CH3), 18.8 
(CH(CH3)CH3), 14.5 (CH2CH3), 13.5 (CH2CH3); IR (CHCl3, cm–1) νmax 1716 (Et2NC=O), 1653 (C=N); 
MS (EI, m/z) 435 (28), 434 (M+, 100), 391 (M+–i-Pr, 3), 361 (8), 334 (M+–CONEt2, 28), 305 (6), 271 
(8), 257 (6),243 (12), 230 (CH2C6H2(O)(oxazoline)CH2+, 40), 100 (60); HRMS Found 434.2569. 
C27H34N2O3 requires 434.2569. 
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(–)-(S,4SP,5RP)-Trifluoromethansulfonic acid [4-(5-(4-isopropyloxazolin-2-yl)-[2.2]paracyclo-
phanyl)] ester (18a) 
A solution of diol 15a (0.19 g, 0.53 mmol) and pyridine (0.1 mL, 1.27 mmol) in DCM (1.5 mL) was 
added dropwise to a solution of Tf2O (0.19 mL, 1.11 mmol) in DCM (0.5 mL) at 0 °C. After stirring for 
1.5 h, the solution was warmed to rt and stirred for a further 2 h. Water (6 mL) was added, the aq layer 
separated and extracted with DCM (3 × 6 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated. Flash column chromatography, gradient elution (pentane:EtOAc = 19:1 -> 
9:1) gave the title compound as a colorless oil (0.18 g, 73%); Rf (petroleum ether:EtOAc = 8:2) 0.52; 
[α]D20 –26 (c 1.35, CHCl3); 1H NMR (400 MHz) δ 6.90 (1 H, dd, J = 7.7, 1.9), 6.82 (1 H, dd, J = 7.7, 
1.7), 6.63 (1 H, dd, J = 7.7, 1.7), 6.62 (1 H, d, J = 8.0), 6.60 (1 H, dd, J = 7.7, 1.9), 6.58 (1 H, d, J = 8.0), 
4.42 (1 H, dd, J = 9.1, 7.7, CHHO), 4.18 (1 H, td, J = 9.1, 6.6, NCH), 4.10 (1 H, dd, J = 9.1, 7.7, 
CHHO), 3.43 (1 H, m), 3.36 (1 H, ddd, J = 13.5, 9.9, 4.1, H-2a), 3.23 (1 H, ddd, J = 12.9, 9.9, 4.1), 3.07-
2.96 (4 H, m), 2.90 (1 H, ddd, J = 13.5, 10.2, 4.1, H-2b), 2.00 (1 H, oct, J = 6.6, CH(CH3)2), 1.13 (3 H, 
d, J = 6.6, CH3), 1.04 (3 H, d, J = 6.6, CH3); 13C NMR (100 MHz) δ 159.3 (C=N), 145.5, 143.5, 139.2, 
138.9, 137.2, 134.3, 132.7, 132.4, 132.3, 131.9, 130.2, 124.1, 118.5 (q, JC-F 317.9, CF3), 73.5 (NCH), 
69.6 (CH2O), 34.8, 34.4, 34.1, 32.6 (CH(CH3)2), 30.8 (C-2), 19.6 (CH3), 18.5 (CH3); 19F NMR (376 
MHz) δ –73.8 (3 F, s); IR (neat, cm–1) νmax 1659 (C=N); MS (EI, m/z) 468 (13), 467 (M+, 44), 424 (M+–
i-Pr,, 2), 335 (29), 334 (M+–Tf, 100), 249 (8), 248 (11), 231 (14), 230 (CH2C6H2(O)(oxazoline)CH2+, 
89), 104 (CH2C6H4CH2+, 19); HRMS Found 467.1379. C23H24SF3NO4 requires 467.1378. 
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(–)-(S,4RP,5SP)-Trifluoromethansulfonic acid [4-(5-(4-isopropyloxazolin-2-yl)-[2.2]paracyclo-
phanyl)] ester (18b) 
Treatment of diol 15b (90 mg, 0.255 mmol) according to the procedure for the synthesis of 18a gave the 
title compound as a colourless oil; Rf (petroleum ether:EtOAc = 8:2) 0.42; [α]D20 –69 (c 0.66, CHCl3); 
1H NMR (300 MHz) δ 6.80 (1 H, dd, J = 7.9, 1.7), 6.75 (1 H, dd, J = 7.9, 1.7), 6.63 (1 H, dd, J = 7.9, 
1.7), 6.61 (2 H, s, H-7, 8), 6.58 (1 H, dd, J = 7.9, 1.7), 4.50 (1 H, dd, J = 9.9, 8.7, CHHO), 4.17 (1 H, t, J 
= 8.7, CHHO), 4.05 (1 H, m, NCH), 3.70 (1 H, ddd, J = 12.1, 9.6, 4.0, H-9a), 3.36 (1 H, ddd, J = 13.4, 
9.9, 3.7), 3.21 (1 H, m), 3.12-2.84 (5 H, m), 1.92 (1 H, oct, J = 6.7, CH(CH3)2), 1.17 (3 H, d, J = 6.7, 
CH3), 1.05 (3 H, d, J = 6.7, CH3); 13C NMR (75 MHz) δ 159.8 (C=N), 145.7, 143.7, 139.2, 139.1, 137.1, 
134.6, 132.7, 132.5, 132.3, 130.1, 124.4,  (q, JC-F 319.5, CF3), 72.9 (NCH), 70.3 (CH2O), 34.7, 34.3, 
34.2, 33.3 (CH(CH3)2), 30.8, 19.4 (CH3), 19.0 (CH3); 19F NMR (376 MHz) δ –73.8 (3 F, s); IR (neat, 
cm–1) νmax 1654 (C=N); MS (EI, m/z) 468 (12), 467 (M+, 39), 424 (M+–i-Pr, 2), 335 (26), 334 (M+–Tf, 
100), 249 (7), 248 (10), 231 (13), 230 (CH2C6H2(O)(oxazoline)CH2+, 85), 104 (CH2C6H4CH2+, 21); 
HRMS Found 467.1378. C23H24SF3NO4 requires 467.1378. 
 
(–)-(S,4SP,5RP)-4-Diphenylphosphinyl-5-(4-iso-propyloxazolin-2-yl)[2.2]paracyclophane (3a) 
Triflate 18a (1.05 g, 2.24 mmol) was dissolved in THF (6.5 mL) and Ph2PK (0.5 M w/v solution in 
THF, 0.43 mL, 0.21 mmol) was added. The solution was stirred at rt for 20 h. Degassed water (75 mL) 
and DCM (45 mL) were added and the mixture shaken vigorously. The aq layer was separated and 
extracted with DCM (45 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated.  Flash column chromatography, gradient elution (petroleum ether:DCM:EtOAc = 32:7:1 -
> 31:7:2) gave the title compound as a white crystalline solid (0.52 g, 46%); Rf (petroleum 
ether:DCM:EtOAc = 7:2:1) 0.55; mp 88.0-91.0 °C; [α]D20 –12 (c 0.30, CHCl3); 1H NMR (300 MHz) δ 
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7.56 (2 H, m), 7.34 (2 H, m), 7.15 (3 H, m), 7.10 (3 H, m), 6.87 (1 H, br.d, J = 8.0), 6.77 (1 H, br.d, J = 
8.0), 6.55 (2 H, m), 6.40 (1 H, d, J = 7.8, H-7), 6.35 (1 H, dd, J = 7.8, JH-P = 3.7, H-8), 3.52 (1 H, t, J = 
8.1, CHHO), 3.33 (1 H, m, NCH), 3.16 (1 H, dd, J = 9.9, 8.1, CHHO), 3.09-2.80 (5 H, m), 2.68 (2 H, 
m), 2.41 (1 H, m, H-2b), 1.65 (1 H, oct, J = 6.7, CH(CH3)2), 0.94 (3 H, d, J = 6.7, CH(CH3)CH3), 0.83 
(3 H, d, J = 6.7, CH(CH3)CH3); 13C NMR (75 MHz) δ 163.2 (C=N), 145.5 (d, JC-P = 8.9), 142.0 (d, JC-P 
= 12.5), 140.1 (d, JC-P = 9.5), 139.5, 138.8, 138.7, 138.3, 138.0, 135.5, 134.6, 133.3, 133.2, 133.0, 132.9, 
131.7, 131.64, 131.57, 131.2, 128.5, 128.4, 128.3, 128.0 (2 C, s), 127.9, 72.7 (NCH), 68.5 (CH2O), 36.4 
(d, JC-P = 6.5, C-2), 34.7, 34.6, 33.5, 32.2 (CH(CH3)2), 19.7 (CH3), 18.2 (CH3); 31P NMR (121 MHz) δ 
0.20; IR (CHCl3, cm–1) νmax 1653 (C=N); MS (EI, m/z) 504 (37), 503 (M+, 100), 502 (17), 488 (M+–Me, 
8) 461 (13), 460 (M+–i-Pr, 39), 434 (17), 433 (36), 432 (45), 413 (9), 412 (31), 358 (15), 357 (24), 356 
(27), 330 (22), 329 (49), 328 (58), 322 (14), 308 (20), 104 (CH2C6H4CH2+, 8); HRMS Found 503.2379. 
C34H34PNO requires 503.2378. 
 
(–)-(S,4RP,5SP)-4-Diphenylphosphinyl-5-(4-iso-propyloxazolin-2-yl)[2.2]paracyclophane (3b) 
Treatment of triflate 18b (0.84 g, 1.81 mmol) according to the procedure for the synthesis of 3a gave the 
title compound as a white crystalline solid (0.59 g, 65%); Rf (petroleum ether:DCM:EtOAc = 7:2:1) 
0.32; mp 170.0-172.0 °C; [α]D20 –242 (c 1.04, CHCl3); 1H NMR (400 MHz) δ 7.58 (2 H, m), 7.45 (2 H, 
m), 7.23-7.18 (6 H, m), 6.81 (1 H, dd, J = 8.0, 1.7), 6.63 (3 H, m), 6.53 (1 H, d, J = 7.7, H-7), 6.42 (1 H, 
dd, J = 7.7, JH-P = 3.8, H-8), 3.79 (1 H, t, J = 8.6, CHHO), 3.68 (1 H, dd, J = 9.9, 8.6, CHHO), 3.63 (1 H, 
ddd, J = 13.0, 12.4, 5.8, H-9a), 3.08 (1 H, ddd, J = 13.2, 9.6, 3.9), 2.99 (2 H, m, NCH, CHHCH2), 2.93-
2.84 (3 H, m), 2.76 (1 H, ddd, J = 13.0, 9.6, 4.7), 2.49 (1 H, ddd, J = 13.7, 9.9, 4.4, H-2b), 1.65 (1 H, m, 
CH(CH3)2), 1.01 (3 H, d, J = 6.6, CH(CH3)CH3), 0.88 (3 H, d, J = 6.9, CH(CH3)CH3); 13C NMR (100 
MHz) δ 162.4 (C=N), 145.4 (d, JC-P = 9.9), 142.0 (d, JC-P = 11.4), 139.4, 138.90, 138.95, 138.0 (d, JC-P = 
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9.1), 137.0, 136.8, 135.3 (2 C, s), 133.4, 133.2, 133.1, 132.9, 132.2, 132.1, 131.4, 130.9, 128.4, 128.34, 
128.26, 128.2, 127.9, 127.8, 72.6 (NCH), 69.3 (CH2O), 36.5 (d, JC-P = 9.1, C-2), 35.0, 34.8, 34.2, 33.1 
(CH(CH3)2), 19.6 (CH(CH3)CH3), 19.2 (CH(CH3)CH3); 31P NMR (162 MHz) δ 1.48; IR (CHCl3, cm–1) 
νmax 1651 (C=N); MS (EI, m/z) 504 (37), 503 (M+, 100), 502 (19), 488 (M+–Me, 10) 461 (10), 460 (M+–
i-Pr, 28), 434 (25), 433 (57), 432 (63), 413 (19), 412 (64), 358 (13), 357 (24), 356 (36), 330 (39), 329 
(75), 328 (93), 322 (27), 308 (22), 104 (CH2C6H4CH2+, 22); HRMS Found 503.2378. C34H34PNO 
requires 503.2378. 
 
(+)-(S,4Rp,12Rp)-4-Di(4-methoxyphenyl)phosphinyl-13-(4-iso-propyloxazolin-2-yl)[2.2]paracyclo-
phane (19a) 
n-BuLi (15% w/v solution in n-hexane, 0.23 mL, 0.53 mmol) was added dropwise to a solution of the 
diastereomeric mixture of bromides 10 (0.14 g, 0.35 mmol) in THF (3.5 mL) at –78 °C to give an orange 
solution. After stirring for 1.5 h, a solution of chlorodi(4-methoxyphenyl)phosphine (0.21 g, 0.74 mmol) 
in THF (0.5 mL) was added dropwise to give a black solution which slowly became orange. After 10 
min, the cooling bath was removed and the reaction mixture stirred for a further 3 h. Ordinary ‘wet’ 
Et3N (0.1 mL, 0.71 mmol) was added followed by Et2O (3 mL) and the resulting mixture added to silica 
gel (1.4 g) and DCM (3 mL). The solvent was evaporated to leave the crude product mixture suspended 
on silica which was added to the top of a column of silica gel for flash chromatography, gradient elution 
(pentane:Et2O = 9:1 -> 8:2 -> 7:3. This gave the title product as a white solid (0.06 g, 32%); Rf 
(petroleum ether:Et2O = 8:2) 0.21; mp 79.0-81.0 °C; [α]D20 +19 (c 0.96, CHCl3); 1H NMR (300 MHz) δ 
7.61 (1 H, br.s, H-13), 7.32 (2 H, br.dd, JH-P = 8.7, J = 7.9, P-C6H4OMe (ortho)), 7.23 (2 H, br.dd, JH-P = 
8.7, J = 7.6, P-C6H4OMe (ortho)), 6.85 (2 H, br.d, J = 7.6, P-C6H4OMe (meta)), 6.77 (2 H, br.d, J = 7.9, 
P-C6H4OMe (meta)), 6.62 (1 H, dd, J = 7.9, 1.7, H-15), 6.58 (1 H, d, J = 7.9, H-16), 6.54 (1 H, dd, J = 
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7.7, 1.8, H-7), 6.45 (1 H, dd, J = 7.7, JH-P = 5.4, H-8), 5.88 (1 H, dd, JH-P = 8.4, J = 1.8, H-5), 4.34 (1 H, 
m, OCHH), 4.18 (1 H, br.dd, J = 12.4, 9.3, H-10a), 3.92 (2 H, m, NCH, OCHH), 3.80 (3 H, s, OCH3), 
3.74 (3 H, s, OCH3), 3.43 (1 H, ddd, J = 12.9, 9.9, 6.7, H-1a), 3.26 (1 H, br.dd, J = 13.6, 9.9, H-2a), 3.02 
(2 H, m, H-1b, 9a), 2.86 (1 H, ddd, J = 12.6, 9.3, 7.4, H-9b), 2.78-2.61 (2 H, m, H-2b, 10b), 1.74 (1 H, 
oct, J = 6.7, CH(CH3)2), 1.00 (3 H, d, J = 6.7, CH3), 0.88 (3 H, d, J = 6.7, CH3); 13C NMR (75 MHz) δ 
161.9 (C=N), 160.4 (MeOC), 159.9 (MeOC), 142.9 (d, JC-P = 17.9), 141.1, 140.1, 139.5, 138.8 (d, JC-P = 
12.0), 137.3, 137.0, 135.3, 134.8, 134.5, 134.2, 134.1, 133.9, 132.6, 130.9 (d, JC-P = 4.7), 130.0 (d, JC-P = 
7.5), 127.9 (d, JC-P = 8.3), 127.6, 113.9, 113.8 (2 C, s), 113.7, 73.6 (NCH), 68.8 (OCH2), 55.13 (OCH3), 
55.06 (OCH3), 36.1 (C-10), 35.3 (d, JC-P = 9.5, C-2), 33.8, 33.0 (2 C, s), 19.3 (CH3), 18.3 (CH3); δP (121 
MHz) –4.64; IR (CHCl3, cm–1) νmax 1642 (C=N); MS (EI, m/z) 564 (33), 563 (M+, 100), 562 (11), 548 
(M+–Me, 4), 460 (M+–i-Pr, 9), 478 (6), 349 (13), 348 (CH2C6H3(P(C6H4OMe)2)CH2+, 50), 347 (13), 282 
(8), 240 (8), 239 (9), 215 (10), 178 (9); HRMS Found 563.2588. C36H38PNO3 requires 563.2589. 
 
(–)-(S,4Sp,12Sp)-4-Di(4-methoxyphenyl)phosphinyl-13-(4-iso-propyloxazolin-2-yl)[2.2]paracyclo-
phane (19b) 
Further elution gave the title compound as a white crystalline solid (0.06 g, 31%); Rf (petroleum 
ether:Et2O = 8:2) 0.08; mp 147.0-149.0 °C; [α]D20 –50 (c 0.87, CHCl3); 1H NMR (300 MHz) δ 7.69 (1 
H, d, J = 1.5, H-13), 7.40 (2 H, dd, J = 8.7, JH-P = 8.2, P-C6H4OMe (ortho)), 7.24 (2 H, br.dd, J = 8.7, JH-
P = 7.2, P-C6H4OMe (ortho)), 6.85 (2 H, br.d, J = 8.7, P-C6H4OMe (meta)), 6.76 (2 H, br.d, J = 8.7, P-
C6H4OMe (meta)), 6.63 (1 H, dd, J = 7.7, 1.5, H-15), 6.59 (1 H, d, J = 7.7, H-16), 6.55 (1 H, dd, J = 7.8, 
1.7, H-7), 6.45 (1 H, dd, J = 7.8, JH-P = 5.7, H-8), 5.89 (1 H, dd, JH-P = 8.4, J = 1.7, H-5), 4.32-4.18 (2 H, 
m, OCHH, H-10a), 4.00-3.90 (2 H, m, NCH, OCHH), 3.79 (3 H, s, OCH3), 3.74 (3 H, s, OCH3), 3.45 (1 
H, ddd, J = 12.9, 9.7, 6.7, H-1a), 3.27 (1 H, br.dd, J = 13.6, 9.7, H-2a), 3.05 (2 H, m, H-1b, 9a), 2.81-
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2.62 (3 H, m, H-9b, H-2b, 10b), 1.53 (1 H, oct, J = 6.7, CH(CH3)2), 1.00 (3 H, d, J = 6.7, CH(CH3)CH3), 
0.88 (3 H, d, J = 6.7, CH(CH3)CH3); 13C NMR (75 MHz) δ 162.7 (C=N), 160.4 (MeOC), 159.9 
(MeOC), 143.0 (d, JC-P = 17.9), 140.8, 139.7, 139.5, 138.7 (d, JC-P = 10.7), 137.7, 137.3, 135.6, 134.9, 
134.4, 134.3, 134.2, 134.1, 132.5, 131.6 (d, JC-P = 4.8), 130.5 (d, JC-P = 7.1), 127.8 (d, JC-P = 7.7), 127.6, 
113.9 (2 C, s), 113.8, 113.7, 73.1 (NCH), 69.1 (OCH2), 55.08 (OCH3), 55.05 (OCH3), 36.4 (C-10), 35.5 
(d, JC-P = 9.5, C-2), 34.0, 33.5 (CH(CH3)2), 33.0, 19.4 (CH(CH3)CH3), 18.9 (CH(CH3)CH3); 31P NMR 
(121 MHz) δ –4.70; IR (CHCl3, cm–1) νmax 1638 (C=N); MS (EI, m/z) 564 (35), 563 (M+, 100), 562 (18), 
548 (M+–Me, 4) 478 (5), 349 (12), 348 (CH2C6H3(P(C6H4OMe)2)CH2+, 49), 347 (12), 282 (8), 240 (7), 
239 (9), 215 (9); HRMS Found 563.2590. C36H38PNO3 requires 563.2589. 
 
(+)-(R,4SP,12SP)-4-Bromo-[2.2]paracyclophane-12-carboxylic acid (1-hydroxymethyl-2-methyl-
propyl)-amide (20a) 
Thionyl chloride (2.47 mL, 33.90 mmol) was added to (±)-bromo-carboxylic acid 933 (1.99 g, 6.02 
mmol) and the resulting mixture heated at 60 °C for 4 h. The excess thionyl chloride was removed by 
evaporation and the final traces by azeotropic distillation with toluene. The resulting crude acid chloride 
was dissolved in DCM (5 mL) and cooled to 0 °C. A solution of D-phenylglycinol (1.64 g, 11.92 mmol) 
and Et3N (1.68 mL, 11.92 mmol) in DCM (6 mL) was added and the reaction mixture allowed to warm 
to rt and stirred for 24 h. DCM was then added (150 mL) and the solution washed with aq NaHCO3 
solution (3.5% w/v, 2 × 150 mL) and brine (150 mL). The organic phase was dried over Na2SO4, filtered 
and concentrated. Flash column chromatography, gradient elution (pentane:DCM:EtOAc = 5:2:3 -> 
4:2:4 -> 3:2:5) was carried out and the title compound was found to crystallize in several of the 
fractions. This was removed by filtration. The remaining fractions consisted of mixtures of both 
diastereoisomers so these were evaporated and recrystallized from EtOAc and a small amount of 
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petroleum ether. This gave more of the pure title compound. This chromatography-recrystallization 
procedure was repeated several times to give the title compound as a white crystalline solid (1.14 g, 
42%); Rf (pentane:DCM:EtOAc = 3:2:5) 0.56; mp 222.5-223.0 °C; [α]D20 +58 (c 0.84, CHCl3); 1H NMR 
(400 MHz) δ 7.40-7.31 (5 H, m, Ph), 7.29 (1 H, d, J = 1.7, H-13), 6.90 (1 H, d, J = 1.7, H-5), 6.65-6.59 
(4 H, m, NH, H-7, 15, 16), 6.54 (1 H, d, J = 7.7, H-8), 5.32 (1 H, ddd, J = 6.0, 5.8, 4.4, NCH), 4.09 (2 H, 
br.s, CH2OH), 3.81 (1 H, m, H-10a), 3.47 (1 H, ddd, J = 13.7, 9.6, 1.9), 3.17 (1 H, ddd, J = 12.9, 9.6, 
6.9), 3.13-3.03 (3 H, m), 2.89-2.79 (2 H, m), 2.64 (1 H, br.s, OH); 13C NMR (75 MHz) δ 169.1 (C=O), 
142.3, 139.9, 139.5, 138.6, 138.5, 136.0, 135.4, 135.0, 134.9, 134.6, 131.5, 128.9 (2 C, s), 127.9, 126.8 
(2 C, s), 126.7, 126.4, 67.2 (CH2OH), 56.3 (NCH), 35.7, 34.7, 34.4, 32.6; IR (KBr, cm–1) νmax 3422 (br., 
O-H), 3315 (N-H), 1639 (C=OONH); MS (EI, m/z) 452 (9), 451 (M+, 35), 450 (14), 449 (M+, 37), 420 
(M+–CH2OH, 6), 419 (5), 418 (M+–CH2OH, 5), 332 (21), 331 (10), 330 (25), 316 (6), 315 (M+–
HOCH2C(Ph)(H)NH, 11), 314 (8), 313 (M+–HOCH2C(Ph)(H)NH, 12), 267 (M+–CH2C6H3(Br)CH2, 32), 
147 (100), 131 (46), 121 (17); HRMS Found 449.0990. C25H24BrNO2 requires 449.0991. 
 
(–)-(R,4RP,12RP)-4-Bromo-[2.2]paracyclophane-12-carboxylic acid (1-hydroxymethyl-2-methyl-
propyl)-amide (20b) 
The title compound was isolated, during the procedure described above, as a white amorphous solid 
(1.30 g, 48%); Rf (pentane:DCM:EtOAc = 3:2:5) 0.49; mp 60.0-62.0 °C; [α]D20 –46 (c 0.81, CHCl3); 1H 
NMR (400 MHz) δ 7.44 (2 H, m, Ph), 7.38-7.31 (3 H, m, Ph), 7.30 (1 H, br.s, H-13), 6.69 (1 H, d, J = 
7.4, NH), 6.61-6.52 (4 H, m), 6.48 (1 H, d, J = 8.0), 5.12 (1 H, m, NCH), 3.85 (2 H, d, J = 4.7, CH2OH), 
3.73 (1 H, ddd, J = 12.4, 6.9, 4.9, H-10a), 3.41 (1 H, ddd, J = 13.5, 9.6, 1.9, H-2a), 3.15-2.93 (5 H, m, 
OH, H-1a, 1b, 9a, 9b), 2.83-2.72 (2 H, m, H-2b, 10b); 13C NMR (100 MHz) δ 168.9 (C=O), 142.0, 
139.7, 139.4, 139.0, 138.4, 135.7, 135.4, 135.0, 134.6, 134.0, 131.2, 128.7 (2 C, s), 127.6, 126.9, 126.7 
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(2 C, s), 126.4, 66.1 (CH2OH), 55.9 (NCH), 35.6 (C-2), 34.7 (C-10), 34.3, 32.4; IR (KBr, cm–1) νmax 
3398 (br., O-H), 3284 (N-H), 1655 (C=OONH); MS (EI, m/z) 452 (10), 451 (M+, 40), 450 (9), 449 (M+, 
38), 421 (5), 420 (M+–CH2OH, 5), 419 (6), 418 (M+–CH2OH, 5), 332 (24), 331 (10), 330 (25), 316 (7), 
315 (M+–HOCH2C(Ph)(H)NH, 10), 314 (8), 313 (M+–HOCH2C(Ph)(H)NH, 10), 267 (M+–
CH2C6H3(Br)CH2, 30), 147 (100), 131 (42), 121 (6); HRMS Found 449.0990. C25H24BrNO2 requires 
449.0991. 
 
(+)-(R,4Sp,12Sp)-4-Bromo-12-(4-phenyloxazolin-2-yl)[2.2]paracyclophane (21a) 
Amide 20a (1.14 g, 2.54 mmol), PPh3 (1.16 g, 4.44 mmol), CCl4 (0.43 mL, 4.44 mmol) and Et3N (0.62 
mL, 4.44 mmol) were dissolved in MeCN (53 mL) and the solution was stirred for 15 h. The reaction 
was monitored by tlc and, in order to force it to completion, an extra eq of PPh3 (0.67 g, 2.54 mmol), 
CCl4 (0.25 mL, 2.54 mmol) and Et3N (0.35 mL, 2.54 mmol) were added and the mixture heated at 50 °C 
for 4 h. DCM (66 mL) was then added and the solution washed with brine (2 × 66 mL), dried over 
MgSO4, filtered and concentrated. Flash column chromatography, gradient elution (pentane:EtOAc = 
24:1 -> 19:1 -> 9:1) gave the title compound as a waxy semi-solid (1.07 g, 97%); Rf (petroleum 
ether:EtOAc = 8:2) 0.63; [α]D20 +28 (c 0.95, CHCl3); 1H NMR (300 MHz) δ 7.80 (1 H, br.s, H-13), 7.39 
(4 H, m, Ph), 7.30 (1 H, m, Ph), 6.69 (1 H, d, J = 1.7, H-5), 6.62 (2 H, m, H-15, 16), 6.57 (1 H, dd, J = 
7.9, 1.7, H-7), 6.50 (1 H, d, J = 7.9, H-8), 5.48 (1 H, dd, J = 10.1, 8.3, NCH), 4.79 (1 H, dd, J = 10.1, 
8.3, OCHH), 4.24 (1 H, ddd, J = 12.6, 9.2, 2.0, H-10a), 4.19 (1 H, t, J = 8.3, OCHH), 3.48 (1 H, ddd, J = 
13.1, 9.7, 1.5, H-2a), 3.22 (1 H, ddd, J = 12.9, 9.9, 6.9), 3.13-2.94 (3 H, m), 2.81 (2 H, m); 13C NMR (75 
MHz) δ 164.8 (C=N), 142.8, 142.1, 140.8, 139.3, 138.8, 135.8, 135.4, 135.1, 135.0, 131.2, 130.6 (C-13), 
128.7 (2 C, s), 127.7, 127.4, 126.7 (2 C, s), 126.6, 74.1 (OCH2), 70.3 (NCH), 36.2, 35.8, 34.0, 32.6; IR 
IR (CHCl3, cm–1) νmax 1632 (C=N); MS (EI, m/z) 434 (14), 433 (M+, 56), 432 (14), 431 (M+, 57), 250 
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(18), 249 (CH2C6H3(oxazoline)CH2+, 100), 248 (12), 158 (54), 131 (12), 104 (12), 103 (20); HRMS 
Found 431.0885. C25H2279BrNO requires 431.0885. 
 
(+)-(R,4Rp,12Rp)-4-Bromo-12-(4-phenyloxazolin-2-yl)[2.2]paracyclophane (21b) 
Treatment of amide 20b (1.29 g, 2.87 mmol) according to the procedure for the synthesis of 21a gave 
the title compound as a white crystalline solid (0.99 g, 80%); Rf (petroleum ether:EtOAc = 8:2) 0.51; mp 
115.0-118.0 °C; [α]D20 +15 (c 0.86, CHCl3); 1H NMR (400 MHz) δ 7.75 (1 H, br.d, J = 1.5, H-13), 7.48-
7.40 (4 H, m, Ph), 7.32 (1 H, m, Ph), 6.66 (1 H, d, J = 1.7, H-5), 6.61 (1 H, d, J = 7.9, H-16), 6.60 (1 H, 
dd, J = 7.9, 1.5, H-15), 6.55 (1 H, dd, J = 8.0, 1.7, H-7), 6.49 (1 H, d, J = 8.0, H-8), 5.39 (1 H, dd, J = 
9.9, 8.2, NCH), 4.70 (1 H, dd, J = 9.9, 8.2, OCHH), 4.29 (1 H, t, J = 8.2, OCHH), 4.28 (1 H, ddd, J = 
13.2, 8.2, 2.5, H-10a), 3.47 (1 H, ddd, J = 13.2, 9.9, 1.7, H-2a), 3.21 (1 H, ddd, J = 12.9, 9.9, 6.6, H-1a), 
3.09 (1 H, m, H-1b), 2.99 (2 H, m, H-9a, 9b), 2.80 (2 H, m, H-10b, 2b); 13C NMR (100 MHz) δ 164.0 
(C=N), 142.7, 142.0, 140.8, 139.1, 138.7, 135.6, 135.2, 135.0, 134.8, 131.2, 130.1 (C-13), 128.7 (2 C, s), 
127.5, 127.4, 126.8 (2 C, s), 126.6, 73.5 (OCH2), 70.8 (NCH), 35.8, 35.7, 33.8 (C-9), 32.6 (C-1); IR 
(CHCl3, cm–1) νmax 1632 (C=N); MS (EI, m/z) 434 (14), 433 (M+, 61), 431 (M+, 58), 250 (18), 249 
(CH2C6H3(oxazoline)CH2+, 100), 248 (12), 158 (51), 131 (15), 104 (12), 103 (19); HRMS Found 
431.0884. C25H2279BrNO requires 431.0885. 
 
(–)-(R,4Sp,12Sp)-4-Di(4-methoxyphenyl)phosphinyl-12-(4-phenyloxazolin-2-yl)[2.2]paracyclophane 
(22a) 
n-BuLi (15% w/v solution in n-hexane, 0.28 mL, 0.65 mmol) was added dropwise to a solution of the 
bromide 21a (0.20 g, 0.47 mmol) in THF (4.7 mL) at –95 °C (obtained by addition of liquid nitrogen to 
a bath of diethyl ether) to give an orange solution which slowly turned dark brown over 4 min. After this 
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time, a solution of chlorodi(4-methoxyphenyl)phosphine (0.26 g, 0.93 mmol) in THF (1.5 mL) was 
added dropwise to give a pale orange solution. After 12 min, the cooling bath was removed and the 
reaction mixture stirred for a further 1.5 h. Ordinary ‘wet’ Et3N (0.13 mL, 0.93 mmol) was then added 
followed by Et2O (4 mL) and the resulting mixture added to silica gel (2.0 g) and DCM (4 mL). The 
solvent was evaporated to leave the crude product mixture suspended on silica which was added to the 
top of a column of silica gel for flash chromatography, gradient elution (petroleum ether:DCM:EtOAc = 
23:6:1 -> 15:4:1). This gave first unreacted starting material 21a (0.08 g, 42%) and then the title 
compound as a white solid (0.16 g, 57%); Rf (petroleum ether:DCM:EtOAc = 7:2:1) 0.45; mp 88.0-90.0 
°C; [α]D20 –26 (c 0.92, CHCl3); 1H NMR (400 MHz) δ 7.70 (1 H, d, J = 1.7, H-13), 7.35 (4 H, m, Ph, P-
C6H4OMe (ortho)), 7.29-7.21 (5 H, m, Ph, P-C6H4OMe (ortho)), 6.83 (2 H, br.d, J = 8.0, P-C6H4OMe 
(meta)), 6.77 (2 H, br.d, J = 8.0, P-C6H4OMe (meta)), 6.67 (1 H, dd, J = 7.9, 1.7, H-15), 6.62 (1 H, d, J 
= 7.9, H-16), 6.57 (1 H, dd, J = 7.7, 1.8, H-7), 6.48 (1 H, dd, J = 7.7, JH-P = 5.8, H-8), 5.93 (1 H, dd, JH-P 
= 8.5, J = 1.8, H-5), 5.24 (1 H, m, NCH), 4.71 (1 H, dd, J = 10.2, 8.2, OCHH), 4.24 (1 H, br.dd, J = 
12.4, 9.4, H-10a), 4.02 (1 H, dd, J = 9.1, 8.2, OCHH), 3.81 (3 H, s, OCH3), 3.75 (3 H, s, OCH3), 3.47 (1 
H, ddd, J = 13.2, 10.1, 6.7, H-1a), 3.30 (1 H, br.dd, J = 13.2, 10.1, H-2a), 3.09 (1 H, m, H-1b), 3.03 (1 
H, m, H-9a), 2.90 (1 H, ddd, J = 12.6, 9.4, 7.4, H-9b), 2.77 (1 H, ddd, J = 12.4, 9.9, 7.4, H-10b), 2.70 (1 
H, m, H-2b); 13C NMR (100 MHz) δ 163.7 (C=N), 160.3 (MeOC), 159.8 (MeOC), 142.8 (d, JC-P = 
19.7), 142.7, 141.3, 140.0, 139.5, 138.7 (d, JC-P = 9.9), 137.3, 137.0, 135.4, 135.1, 134.4, 134.2, 134.1, 
134.0, 132.6 (C-13), 131.1 (d, JC-P = 5.3), 129.9 (d, JC-P = 7.0), 128.6 (2 C, s), 127.8 (d, JC-P = 7.6), 
127.3, 127.2, 126.6 (2 C, s), 113.9, 113.8 (2 C, s), 113.7, 73.4 (OCH2), 70.8 (NCH), 55.2 (OCH3), 55.1 
(OCH3), 36.2 (C-10), 35.4 (d, JC-P = 9.8, C-2), 33.9 (C-9), 33.1 (C-1); 31P NMR (121 MHz) δ –4.72; IR 
(KBr, cm–1) νmax 1636 (C=N); MS (EI, m/z) 598 (37), 597 (M+, 100), 596 (23), 568 (M+–OMe, 5), 478 
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(5), 449 (3%), 349 (17), 348 (CH2C6H3(P(C6H4OMe)2)CH2+, 63), 347 (14), 317 (7), 299 (10), 249 (6), 
240 (11), 239 (19), 209 (6); HRMS Found 597.2433. C39H36PNO3 requires 597.2433. 
 
(+)-(R,4Sp)-4-(4-phenyloxazolin-2-yl)[2.2]paracyclophane 
O
N
Ph
 
The title compound was sometimes isolated as a by-product from the above synthesis. Pale yellow solid; 
mp 124.5-125.0 °C; [α]D20 +115 (c 0.83, CHCl3); 1H NMR (400 MHz) δ 7.39 (4 H, m, Ph), 7.31 (1 H, 
m, Ph), 7.16 (1 H, br.s, H-5), 6.64 (2 H, m), 6.54 (4 H, m), 5.47 (1 H, br.t, J = 8.8, NCH), 4.80 (1 H, dd, 
J = 9.9, 8.8, OCHH), 4.21 (2 H, m, OCHH, H-2a), 3.20-2.98 (6 H, m, H-1a, 1b, 9a, 9b, 10a, 10b), 2.88 
(1 H, ddd, J = 13.2, 9.9, 6.9, H-2b); 13C NMR (100 MHz) δ 165.0 (C=N), 142.6, 141.2, 139.8, 139.6, 
139.3, 135.8, 135.0, 134.4, 132.9, 132.7, 132.2, 131.2, 128.7 (2 C, s), 128.0, 127.5, 126.7 (2 C, s), 74.2 
(OCH2), 70.4 (NCH), 36.1 (C-2), 35.4, 35.1, 35.0; IR (KBr, cm–1) νmax 1624 (C=N); m/z (EI, m/z) 354 
(28), 353 (M+, 100), 250 (17), 249 (CH2C6H3(oxazoline)CH2+, 93), 248 (12), 158 (51), 131 (9), 105 (26), 
104 (CH2C6H4CH2+, 23%), 103 (18%); HRMS 353.177981. C25H23NO requires 353.177964. 
 
(+)-(R,4Rp,12Rp)-4-Di(4-methoxyphenyl)phosphinyl-12-(4-phenyloxazolin-2-yl)[2.2]paracyclo-
phane (22b) 
n-BuLi (15% w/v solution in n-hexane, 0.15 mL, 0.35 mmol) was added dropwise to a solution of 
bromide 21b (0.10 g, 0.23 mmol) in THF (2.3 mL) at –78 °C. The resulting orange solution was stirred 
for 2 h, after which time a solution of chlorodi(4-methoxyphenyl)phosphine (0.14 g, 0.49 mmol) in THF 
(0.7 mL) was added dropwise to give a pale yellow solution. After 15 min, the cooling bath was 
removed and the reaction mixture stirred for a further 2 h. Ordinary ‘wet’ Et3N (0.06 mL, 0.46 mmol) 
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was added followed by Et2O (2 mL) and the resulting mixture added to silica gel (1.0 g) and DCM (2 
mL). The solvent was evaporated to leave the crude product mixture suspended on silica which was 
added to the top of a column of silica gel for flash chromatography, gradient elution 
(pentane:DCM:EtOAc = 23:6:1 -> 7:2:1. This gave the product as a white solid (0.10 g, 70%); Rf 
(petroleum ether:DCM:EtOAc = 7:2:1) 0.39; mp 208.0-210.0 °C; [α]D20 +131 (c 0.77, CHCl3); 1H NMR 
(400 MHz) δ 7.69 (1 H, d, J = 1.5, H-13), 7.39 (2 H, t, J = 8.6, JH-P  = 8.6, P-C6H4OMe (ortho)), 7.26 (5 
H, m, Ph, P-C6H4OMe (ortho)), 7.08 (2 H, m, Ph), 6.77 (2 H, br.d, J = 8.6, P-C6H4OMe (meta)), 6.73 (2 
H, br.d, J = 8.0, P-C6H4OMe (meta)), 6.67 (1 H, dd, J = 7.9, 1.5, H-15), 6.62 (1 H, d, J = 7.9, H-16), 
6.56 (1 H, dd, J = 7.6, 1.8, H-7), 6.48 (1 H, dd, J = 7.6, JH-P = 5.5, H-8), 6.00 (1 H, dd, JH-P = 8.2, J = 
1.8, H-5), 5.27 (1 H, dd, J = 10.2, 8.2, NCH), 4.62 (1 H, dd, J = 10.2, 8.2, OCHH), 4.26 (1 H, m, H-
10a), 4.17 (1 H, t, J = 8.2, OCHH), 3.74 (3 H, s, OCH3), 3.59 (3 H, s, OCH3), 3.48 (1 H, ddd, J = 12.8, 
9.9, 7.1, H-1a), 3.29 (1 H, br.dd, J = 13.5, 9.9, H-2a), 3.08 (1 H, br.dd, J = 12.8, 10.4, H-1b), 3.02 (1 H, 
m, H-9a), 2.77-2.65 (3 H, m, H-9b, 10b, 2b); 13C NMR (75 MHz) δ 163.9 (C=N), 160.4 (MeOC), 159.9 
(MeOC), 143.0 (d, JC-P = 17.9), 142.6, 141.4, 139.9, 139.7, 138.9 (d, JC-P = 10.7), 137.6, 137.3, 135.7, 
135.3, 134.4 (3 C, s), 134.1, 132.5 (C-13), 131.8 (d, JC-P = 4.8), 130.4 (d, JC-P = 7.2), 128.6 (2 C, s), 
127.6 (d, JC-P = 7.7), 127.3, 127.1, 126.8 (2 C, s), 114.0, 113.9 (2 C, s), 113.8, 73.2 (OCH2), 70.5 
(NCH), 55.0 (OCH3), 54.9 (OCH3), 36.5 (C-10), 35.5 (d, JC-P = 9.5, C-2), 34.2 (C-9), 32.9 (C-1); 31P 
NMR (121 MHz) δ –4.67; IR (KBr, cm–1) νmax 1630 (C=N); MS (EI, m/z) 598 (37), 597 (M+, 100), 596 
(19), 568 (M+–OMe, 5), 493 (5), 349 (17), 348 (CH2C6H3(P(C6H4OMe)2)CH2+, 61), 347 (15), 317 (7), 
299 (9), 249 (8), 240 (11), 239 (20), 225 (5), 209 (7); HRMS Found 597.2434. C39H36PNO3 requires 
597.2433. 
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(+)-(R,4Rp)-4-(4-phenyloxazolin-2-yl)[2.2]paracyclophane 
O
N
Ph
 
The title compound was sometimes isolated as a by-product from the above synthesis. Pale yellow solid; 
mp 148.0-148.5 °C; [α]D20 –72 (c 0.97, CHCl3); 1H NMR (400 MHz) δ 7.40 (4 H, m, Ph), 7.32 (1 H, m, 
Ph), 7.16 (1 H, br.s, H-5), 6.62 (2 H, m), 6.53 (4 H, m), 5.43 (1 H, dd, J = 10.2, 8.2, NCH), 4.76 (1 H, 
dd, J = 10.2, 8.2, OCHH), 4.28 (1 H, t, J = 8.2, OCHH), 4.26 (1 H, ddd, J = 13.0, 9.6, 2.2, H-2a), 3.20-
2.97 (6 H, m, H-1a, 1b, 9a, 9b, 10a, 10b), 2.87 (1 H, ddd, J = 13.0, 10.2, 6.6, H-2b); 13C NMR (100 
MHz) δ 164.7 (C=N), 142.7, 141.2, 139.8, 139.5, 139.3, 135.9, 135.1, 134.4, 132.9, 132.7, 132.3, 131.3, 
128.7 (2 C, s), 127.9, 127.5, 126.7 (2 C, s), 73.9 (OCH2), 70.4 (NCH), 35.9 (C-2), 35.4, 35.1, 35.0; IR 
(IR (KBr, cm–1) νmax 1636 (C=N); MS (EI, m/z) 354 (25), 353 (M+, 100), 250 (16), 249 
(CH2C6H3(oxazoline)CH2+, 87), 248 (13), 158 (50), 131 (11), 105 (26), 104 (CH2C6H4CH2+, 23%), 103 
(18%); HRMS Found 353.1780. C25H23NO requires 353.1780. 
 
General procedure for the palladium-catalyzed allylic alkylation of 1,3-diphenyl-2-propenyl 
acetate25 
[Pd(η3-C3H5)Cl]2 (3.7 mg, 0.01 mmol) and the appropriate ligand (0.03 mmol) were dissolved in toluene 
(2.0 mL) and stirred for 1 h. A solution of 1,3-diphenyl-2-propenyl acetate41 (0.13 g, 0.50 mmol) in 
toluene (1.0 mL) was added and the solution stirred for 0.5 h. Dimethylmalonate (0.17 mL, 1.50 mmol), 
then N,O-bis(trimethylsilyl)acetamide (0.37 mL, 1.50 mmol), then LiOAc (1 mg, 0.015 mmol) were 
added. The reaction was monitored by tlc [SM: Rf (petroleum ether:EtOAc = 9:1) 0.51, product: Rf 0.34] 
until completion. DCM (15 mL) was then added, the solution washed with aq saturated NH4Cl solution 
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(2 × 10 mL), dried over MgSO4, filtered and concentrated. Flash column chromatography (petroleum 
ether:EtOAc = 9:1) gave the product as a clear oil which slowly crystallized. The ee was determined by 
HPLC analysis (Chiralcel AD column, heptane:i-PrOH = 95:5), flow rate = 0.5 mL min–1, tR = 30.6 min, 
tS = 43.3 min]. 
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